ParkerVision (PRKR) 10-K 29 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 15, 2022	Jun. 30, 2021
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	000-22904
Entity Registrant Name	PARKERVISION, INC.
Entity Central Index Key	0000914139
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	59-2971472
Entity Address, Address Line One	4446-1A Hendricks Avenue
Entity Address, Address Line Two	Suite 354
Entity Address, City or Town	Jacksonville
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32207
City Area Code	904
Local Phone Number	732-6100
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Public Float			$ 101,605,881
Entity Common Stock, Shares Outstanding		77,766,448
Amendment Flag	false
Auditor Firm ID	569
Auditor Location	Fort Lauderdale, Florida
Auditor Name	MSL, P.A

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 1,030	$ 1,627
Prepaid expenses	574	599
Other current assets	25	8
Total current assets	1,629	2,234
Property and equipment, net	7	30
Intangible assets, net	1,785	2,170
Operating lease right-of-use assets	7	10
Other assets, net	12	12
Total assets	3,440	4,456
CURRENT LIABILITIES:
Accounts payable	706	4,318
Accrued expenses:
Salaries and wages	27	19
Professional fees	109	128
Statutory court costs		251
Other accrued expenses	555	936
Related party note payable, current portion	94	100
Secured note payable, current portion		26
Unsecured notes payable		65
Operating lease liabilities, current portion	155	146
Total current liabilities	1,646	5,989
LONG-TERM LIABILITES:
Secured contingent payment obligation	37,372	33,057
Unsecured contingent payment obligations	5,691	5,222
Convertible notes	2,895	3,018
Related party note payable, net of current portion	609	703
Operating lease liabilities, net of current portion	4	159
Other long-term liabilities		129
Total long-term liabilities	46,571	42,288
Total liabilities	48,217	48,277
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 150,000 and 140,000 shares authorized, 76,992 and 58,591 issued and outstanding at December 31, 2021 and 2020, respectively	770	586
Additional paid-in capital	387,865	376,954
Accumulated deficit	(433,412)	(421,361)
Total shareholders' deficit	(44,777)	(43,821)
Total liabilities and shareholders' deficit	$ 3,440	$ 4,456

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	140,000,000
Common stock, shares issued	76,992,000	58,591,000
Common stock, shares outstanding	76,992,000	58,591,000

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements Of Comprehensive Loss [Abstract]
Revenue	$ 144
Cost of sales	(5)
Gross margin	139
Selling, general and administrative expenses	8,088	10,664
Total operating expenses	8,088	10,664
Interest and other income	242
Interest and other expense	(251)	(547)
Change in fair value of contingent payment obligations	(4,372)	(8,367)
Total interest and other	(4,381)	(8,914)
Net loss before income tax	(12,330)	(19,578)
Income tax expense
Net loss	(12,330)	(19,578)
Other comprehensive loss, net of tax
Comprehensive loss	$ (12,330)	$ (19,578)
Basic and diluted net loss per common share	$ (0.17)	$ (0.42)
Weighted average common shares outstanding	71,299	47,019

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders' Deficit - USD ($) $ in Thousands	Common Stock [Member]Long-term Debt [Member]	Common Stock [Member]Short-term Debt [Member]	Common Stock [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Long-term Debt [Member]	Additional Paid-in Capital [Member]Short-term Debt [Member]	Additional Paid-in Capital [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit [Member]	Long-term Debt [Member]	Short-term Debt [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Total
Balance, value at Dec. 31, 2019				$ 341				$ 368,345		$ (401,783)				$ (33,097)
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights			$ 148				$ 4,618						$ 4,766
Issuance of common stock upon exercise of options and warrants				45				1,530						1,575
Issuance of common stock and warrants for services				7				297						304
Issuance of convertible debt with beneficial conversion feature								173						173
Issuance of common stock upon conversion	$ 15	$ 22			$ 437	$ 318					$ 452	$ 340
Share-based compensation, net of shares withheld for taxes				8				1,236						1,244
Comprehensive loss for the period										(19,578)				(19,578)
Balance, value at Dec. 31, 2020				586			$ (1,126)	376,954	$ 279	(421,361)			$ (847)	(43,821)
Issuance of common stock and warrants in private offerings, net of issuance costs and initial fair value of contingent payment rights				73				5,701						5,774
Issuance of common stock upon exercise of options and warrants				63				959						1,022
Issuance of common stock and warrants for services				9				863						872
Issuance of common stock upon conversion	$ 37				$ 1,201						$ 1,238
Share-based compensation, net of shares withheld for taxes				2				3,313						3,315
Comprehensive loss for the period										(12,330)				(12,330)
Balance, value at Dec. 31, 2021				$ 770				$ 387,865		$ (433,412)				$ (44,777)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,330)	$ (19,578)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	368	632
Share-based compensation	3,315	1,244
Noncash lease expense	3	61
Change in fair value of contingent payment obligation	4,372	8,367
Loss on disposal/impairment of equipment and other assets	43	487
Loan forgiveness	(194)
Noncash expense for amendment of equity-related agreements		2,211
Changes in operating assets and liabilities:
Prepaid expenses and other assets	784	292
Accounts payable and accrued expenses	(3,917)	1,757
Operating lease liabilities	(146)	(250)
Total adjustments	4,628	14,801
Net cash used in operating activities	(7,702)	(4,777)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment		2
Purchases of property and equipment	(3)	(3)
Net cash used in investing activities	(3)	(1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock, including contingent payment rights in private offerings	6,186	4,801
Net proceeds from exercise of options and warrants	1,022	1,575
Net proceeds from debt financings		1,244
Debt repayments	(100)	(1,272)
Net cash provided by financing activities	7,108	6,348
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(597)	1,570
CASH AND CASH EQUIVALENTS, beginning of year	1,627	57
CASH AND CASH EQUIVALENTS, end of year	1,030	1,627
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	17	61
Cash paid for income taxes

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Significant Accounting Policies	1. SIGNIFICANT ACCOUNTING POLICIES ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware technologies and products. We have determined that our business currently operates under a single operating and reportable segment. We have designed and developed proprietary radio frequency (“RF”) technologies and integrated circuits based on those technologies, and we license our technologies to others for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against providers of mobile handsets, smart televisions and other WiFi products and, in certain cases, their chip suppliers for the infringement of a number of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization. Basis of PresentationOur consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Cash and Cash EquivalentsWe consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives: Manufacturing and office equipment5-7 yearsLeasehold improvementsShorter of useful life or remaining life of leaseFurniture and fixtures7 yearsComputer equipment and software3-5 years The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets. Intangible AssetsWe capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists. As part of our ongoing patent maintenance program, we will, from time to time, abandon a particular patent if we determine fees to maintain the patent exceed its expected recoverability. The cost and accumulated amortization of abandoned intangible assets are removed from their respective accounts, and any resulting net loss is recognized in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss. Contingent Payment ObligationsWe have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our payment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our contingent payment obligations at their estimated fair values in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured and unsecured contingent payment obligations falls within Level 3 in the fair value hierarchy, which involves significant estimates, and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 10). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligations.” LeasesWe have accounted for our finance and operating leases in accordance with ASC 842, “Leases” which requires the recognition of lease right-of-use (“ROU”) assets and lease liabilities on our consolidated balance sheets for finance and operating leases with initial lease terms of more than 12 months. At inception of a lease, we determine if an arrangement contains a lease and whether that lease meets the classification criteria of a finance or operating lease. Some of our lease arrangements contain lease components (e.g. minimum rent payments) and non-lease components (e.g. services). For certain equipment leases, we account for lease and non-lease components separately based on a relative fair market value basis. For all other leases, we account for the lease and non-lease components (e.g. common area maintenance) on a combined basis. For operating leases with terms greater than 12 months, we record the ROU asset and lease obligation at the present value of lease payments over the term using the implicit interest rate, when readily available, or our incremental borrowing rate for collateralized debt based on information available at the lease commencement date. Certain of our leases include rental escalation clauses, renewal options and/or termination options that are factored into our determination of lease payments when it is reasonably certain that the option will be exercised. We do not recognize ROU assets and lease liabilities for leases with terms at inception of twelve months or less. Finance leases are included in property and equipment and other accrued expenses on the consolidated balance sheets. Finance leases are recorded as an asset and an obligation at an amount equal to the present value of the minimum lease payments during the lease term. Amortization expense and interest expense associated with finance leases are included in selling, general, and administrative expense and interest expense, respectively, on the consolidated statements of comprehensive loss. Refer to Note 8 for additional disclosures related to our leases. Convertible DebtWe have issued debt that is convertible, at the holder’s option, into shares of our common stock at fixed conversion prices. Certain of the convertible notes were issued with conversion prices that were below market value of our common stock on the closing date resulting in a beneficial conversion feature which we recorded to equity with a corresponding discount to the debt that was amortized over the life of the notes as interest expense. Effective January 1, 2021, we adopted Accounting Standards Update (“ASU”) 2020-06 "Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."  This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features.  The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception.  The ASU also simplifies the diluted earnings per share calculation in certain areas.  For smaller reporting companies, the ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020.  The ASU provides for a modified retrospective method of adoption whereby the guidance is applied to transactions outstanding at the beginning of the fiscal year of adoption with the cumulative effect of the change being recorded as an adjustment to beginning retained earnings. Adoption of ASU 2020-06 resulted in an increase to our long-term debt of approximately $0.8 million, a decrease in additional paid-in-capital of approximately $1.1 million, and an adjustment to our beginning accumulated deficit of $0.3 million resulting from the elimination of the previously recognized beneficial conversion feature as a debt discount. Revenue RecognitionWe account for revenue under ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. These steps include (1) identifying the contract with the customer, (2) identifying the performance obligations, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing revenue as the entity satisfies the performance obligation(s). Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third parties that utilize or have utilized our intellectual property without a license. As a result, we may receive payments as part of a settlement or in the form of court-awarded damages for a patent infringement dispute. The timing and amount of revenue recognized from each licensee depend upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Such agreements are often complex and may include multiple performance obligations. These agreements can include performance obligations related to the settlement of past patent infringement liabilities, royalties on future covered products sold by licensees, access to a portfolio of technology as it exists at a point in time, and/or promises to provide technology updates to the portfolio during the term of the license. Refer to Note 3 for additional disclosures related to our revenue. Cost of SalesCost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not directly related to revenue generating licensing activities are included in selling, general, and administrative expenses in our consolidated statements of comprehensive loss. Accounting for Share-Based CompensationWe have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur. Income TaxesThe provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return. Loss per Common ShareBasic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive. The number of shares underlying outstanding options, warrants, unvested RSUs, and convertible notes at December 31, 2021 and 2020 were as follows (in thousands): 2021 2020Options outstanding 23,215 12,240Warrants outstanding 10,346 12,850Unvested RSUs - 187Shares underlying convertible notes 20,157 23,557 53,718 48,834 These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Liquidity And Going Concern

Liquidity And Going Concern	12 Months Ended
	Dec. 31, 2021
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern	2. LIQUIDITY AND GOING CONCERN The accompanying consolidated financial statements as of and for the year ended December 31, 2021 were prepared assuming we will continue as a going concern, which contemplates that we will continue in operation and will be able to realize our assets and settle our liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these consolidated financial statements. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern. We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity and equity-linked securities and our contingent funding arrangements with third-parties to fund our operations, including our litigation costs. For the year ended December 31, 2021, we incurred a net loss of approximately $12.3 million and negative cash flows from operations of approximately $7.7 million. At December 31, 2021, we had an accumulated deficit of approximately $433.4 million. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year after the issuance date of these consolidated financial statements. We had cash and cash equivalents of approximately $1.0 million at December 31, 2021. Our remaining capital resources will be used to fund our current obligations and ongoing operating costs; however these resources will not be sufficient to meet our liquidity needs for the next twelve months and we will be required to seek additional capital. Our business plan is currently focused solely on our patent enforcement and technology licensing objectives. The timing and amount of proceeds from our patent enforcement actions are difficult to predict and there can be no assurance we will receive any proceeds from these enforcement actions. Refer to Note 12 for a complete discussion of our patent enforcement proceedings. Our ability to meet our liquidity needs for the twelve months after the issuance date of these financial statements is dependent upon one or more of (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations and (ii) our ability to raise additional capital from the sale of debt or equity securities or other financing arrangements. We anticipate that we will continue to invest in patent protection, licensing, and enforcement of our wireless technologies. We expect that revenue generated from patent enforcement actions, and technology licenses over the twelve months after the issuance date of these financial statements, if any, after deduction of payment obligations to our third-party litigation funder and legal counsel, may not be sufficient to cover our operating expenses. In the event we do not generate revenues, or other patent-asset proceeds, sufficient to cover our operational costs and contingent repayment obligation, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements. The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation and other long-term debt repayment obligations. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our short and long-term liquidity needs and achieve our intended long-term business objectives.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue [Abstract]
Revenue	3. REVENUE During the year ended December 31, 2021, we recognized $0.14 million of revenue derived from contracts with two licensees. The contracts provide access to specified patented technologies as they exist at a point in time and we have no obligation to provide any future updates. The consideration received by us was negotiated as part of a settlement of patent litigation where no prior license agreement existed. The performance obligations were satisfied upon our dismissal of patent enforcement actions with each licensee which was contingent upon our receipt of the negotiated and agreed-upon lump-sum payments from the licensees. The contracts included no variable consideration. All consideration received was recorded to licensing revenue as there were no other material components of the contracts. No contract assets or liabilities exist as of December 31, 2021. We recognized no revenue during the year ended December 31, 2020.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses [Abstract]
Prepaid Expenses	4. PREPAID EXPENSES Prepaid expenses consisted of the following at December 31, 2021 and 2020 (in thousands): 2021 2020Prepaid services$ 523 $ 408Prepaid bonds for German statutory costs - 142Prepaid insurance 23 21Prepaid licenses, software tools and support 16 11Other prepaid expenses 12 17  $ 574 $ 599  Prepaid services at December 31, 2021 and 2020 include approximately $0.5 million and $0.1 million, respectively, of consulting services paid in shares of stock or warrants to purchase shares of stock in the future.

Property And Equipment, Net

Property And Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property And Equipment, Net [Abstract]
Property And Equipment, Net	5. PROPERTY AND EQUIPMENT, NET Property and equipment, at cost, consisted of the following at December 31, 2021 and 2020 (in thousands): 2021 2020Equipment and software$ 221 $ 218Leasehold improvements 19 19Furniture and fixtures - 30 240 267Less accumulated depreciation (233) (237) $ 7 $ 30 Depreciation expense related to property and equipment was approximately $0.01 million and $0.03 million in 2021 and 2020, respectively. For the years ended December 31, 2021 and 2020, we recorded a loss on disposal of fixed assets of approximately $0.01 million and $0.02 million, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Intangible Assets [Abstract]
Intangible Assets	6. INTANGIBLE ASSETS Intangible assets consisted of the following at December 31, 2021 and 2020 (in thousands): 2021 2020 Patents and copyrights$ 14,755 $ 14,948Less accumulated amortization (12,970) (12,778) $ 1,785 $ 2,170 Amortization expense for the years ended December 31, 2021 and 2020 was approximately $0.35 million and $0.45 million, respectively. For the years ended December 31, 2021 and 2020, we recorded losses on the disposal of intangible assets of approximately $0.03 million and $0.3 million, respectively. Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2021 is as follows (in thousands): 2022$ 3092023 2782024 2652025 2262026 1552027 and thereafter 552Total$ 1,785

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
Accrued Liabilities	7. ACCRUED LIABILITIES Other accrued expenses consisted of the following at December 31, 2021 and 2020 (in thousands): 2021 2020Advances$ 500 $ 882Other accrued expenses 55 54 $ 555 $ 936 Advances include amounts received from litigation counsel as advanced reimbursement of out-of-pocket expenses expected to be incurred by us and, at December 31, 2020, includes approximately $0.4 million received from investors for the purchase of equity securities in a January 2021 transaction (see Note 13).

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	8. LEASES We lease our office and other facilities and certain office equipment under long-term, non-cancelable operating leases. No new finance or operating leases commenced during the years ended December 31, 2021 or 2020 except with respect to a sublease agreement for our Lake Mary facility in 2021 as discussed more fully below. During the year ended December 31, 2020, we recognized an impairment loss of approximately $0.2 million on the ROU asset related to our Lake Mary office lease.  We ceased use of this facility in 2018 as part of a restructuring of our operations.  The original value of our ROU asset included estimated future sublease income.  Due to a number of factors, including the high vacancy rate of the building in which the space is located and the pandemic, we determined securing a sublease for the space would be unlikely.  The impairment loss recognized in 2020 represented the remaining carrying value of the asset and is included in selling, general, and administrative expenses in our consolidated statements of comprehensive loss. During the year ended December 31, 2021, we entered into a sublease agreement for this facility for the remaining term of our original lease, through November 2022. The sublease is accounted for as an operating lease. Lease expense for operating leases is generally recognized on a straight-line basis over the lease term and is included in operating expenses on the consolidated statement of comprehensive loss. We recognized operating lease costs of $0.04 million and $0.1 million for the years ended December 31, 2021 and 2020, respectively.  Rental income recognized of $0.05 million for the year ended December 31, 2021, is included in “Interest and other income” in the accompanying consolidated statements of comprehensive loss.‎ Supplemental Cash Flow Information The following table summarizes the supplemental cash flow information related to leases (in thousands): Year Ended Year Ended December 31, December 31, 2021 2020Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 181 $ 315 Cash received for amounts included in the measurement of sublease assets: Operating cash flows from operating subleases 44 - Other Information The table below summarizes other supplemental information related to leases: December 31, December 31, 2021 2020Weighted-average remaining lease term (in years): Operating leases 0.9 1.7 Operating subleases 0.9 -Weighted average discount rate Operating leases (1) 12.2% 12.1% (1)Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019. Undiscounted Cash Flows The future maturities of lease liabilities and sublease receivables consist of the following as of December 31, 2021 (in thousands): Operating Leases Operating Subleases2022 $ 166 $ (120)2023 4 -Thereafter - -Total undiscounted lease payments (receipts) 170 (120)Less: imputed interest (11) -Present value of lease liabilities (receivables) 159 (120)Less: current portion (155) 120Long-term lease obligations $ 4 $ -

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2021
Debt [Abstract]
Long-Term Debt	9. LONG-TERM DEBT Notes Payable Note Payable to a Related PartyWe have an unsecured promissory note payable of $0.7 million to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party (see Note 15), for outstanding unpaid fees for legal services. The note, as amended, accrues interest at 4% per annum and provides for monthly payments of principal and interest of $10,000 with a final balloon payment of approximately $0.59 million due at the maturity date of April 30, 2023. We are currently in compliance with all the terms of the note, as amended. For each of the years ended December 31, 2021 and 2020, we recognized interest expense of approximately $0.03 million related to this note. Unsecured Notes Payable Unsecured notes payable at December 31, 2020 represents the current portion of our Paycheck Protection Program loan. In May 2020, we received approximately $0.2 million in proceeds from an approved loan under the Paycheck Protection Program.  The loan was eligible for forgiveness provided that (i) we used the loan proceeds exclusively for allowed costs including payroll, employee group health benefits, rent and utilities and (ii) employee and compensation levels were maintained during the coverage period. We applied for loan forgiveness in April 2021 and the loan was forgiven in June 2021. The forgiveness of the loan was recognized as income and is included in “Interest and other income” in the accompanying consolidated statements of comprehensive loss for the year ended December 31, 2021. Secured Note PayableOur secured note payable as of December 31, 2020 represented default interest accrued related to a note payable to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz”) for outstanding fees and expenses. Additionally, as of December 31, 2020, we had approximately $3.1 million in accounts payable to Mintz for outstanding fees and expenses. We also had approximately $3.6 million in disputed legal fees and expenses billed by Mintz that we treated as a loss contingency that was not probable as of December 31, 2020 and accordingly, for which we recognized no expense in the consolidated financial statements. On March 29, 2021, we entered into an agreement with Mintz to satisfy our outstanding obligations to Mintz. Under the terms of the agreement, (i) Mintz waived all past defaults on the note resulting in a reversal of previously accrued interest, (ii) we paid Mintz a lump-sum payment of $3.0 million in satisfaction of all outstanding obligations including our accounts payable to Mintz and all disputed and unrecorded billings, and (iii) Mintz agreed to a significant reduction in future success fees that might be payable to Mintz from future patent-related proceeds. At December 31, 2021, the aggregate maturities of our notes payable are as follows (in thousands): 2022$ 942023 609Total$ 703 The estimated fair value of our notes payable at December 31, 2021 is approximately $0.63 million based on a risk-adjusted discount rate. Convertible Notes Our convertible notes represent five-year promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. Interest payments are made on a quarterly basis and are payable, at our option and subject to certain equity conditions, in either cash, shares of our common stock, or a combination thereof. The number of shares issued for interest is determined by dividing the interest payment amount by the closing price of our common stock on the trading day immediately prior to the scheduled interest payment date. To date, all interest payments on the convertible notes have been made in shares of our common stock. We have recognized the convertible notes as debt in our consolidated financial statements. The fixed conversion prices of certain of the notes were below the market value of our common stock on the closing date resulting in the recognition of a beneficial conversion feature that was recorded as a discount on the convertible notes with a corresponding increase to additional paid in capital. Upon our adoption of ASU 2020-06 on January 1, 2021, the previously recognized beneficial conversion feature was eliminated resulting in an increase in convertible notes of $0.8 million (see Note 1). Convertible notes payable at December 31, 2021 and 2020, consist of the following (in thousands): Fixed Conversion Interest December 31,Description Rate Rate Maturity Date 2021 2020Convertible notes dated September 10, 2018 $0.40 8.0% September 10, 2023 $ 200 $ 600Convertible notes dated September 19, 2018 $0.57 8.0% September 19, 2023 425  425 Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 750 1,300 Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 320 340Convertible notes dated July 18, 2019 $0.08 7.5% July 18, 2024 700  700 Convertible notes dated September 13, 2019 $0.10 8.0% September 13, 2024 50  50 Convertible notes dated January 8, 2020 $0.13 8.0% January 8, 2025 1 450  450Total principal balance 2,895 3,865Less unamortized discount - 847 $ 2,895 $ 3,018 1 The maturity date may be extended by one-year increments for up to an additional five years at the holder’s option at a reduced interest rate of 2%. We have the option to prepay the majority of the notes any time following the one-year anniversary of the issuance of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter. The notes provide for events of default that include failure to pay principal or interest when due, breach of any of the representations, warranties, covenants or agreements made by us, events of liquidation or bankruptcy, and a change in control. In the event of default, the interest rate increases to 12% per annum and the outstanding principal balance of the notes plus all accrued interest due may be declared immediately payable by the holders of a majority of the then outstanding principal balance of the notes. For the year ended December 31, 2021, convertible notes with a face value of $0.97 million were converted by the holders into 3.4 million shares of our common stock at an average conversion price of $0.29. For the year ended December 31, 2020, convertible notes with a face value of $0.15 million were converted by the holders into 0.75 million shares of our common stock at an average conversion price of $0.20. At the holders’ option, subject to ownership limitations, the convertible notes outstanding at December 31, 2021 could be converted into an aggregate of approximately 20.2 million shares of our common stock based on the fixed conversion prices. For the years ended December 31, 2021 and 2020, we recognized interest expense of approximately $0.26 million and $0.47 million, respectively. Interest expense for the year ended December 31, 2020 included approximately $0.17 million related to amortization of the discount that was subsequently eliminated upon our adoption of ASU 2020-06. We have elected to pay contractual interest in shares of our common stock. For the years ended December 31, 2021 and 2020, we issued approximately 272,000 and 710,000 shares of our common stock, respectively, as interest-in-kind payments on our convertible notes. All of the shares underlying our convertible notes, including shares reserved for future in-kind interest payments on the notes, have been registered for resale. At December 31, 2021, we estimate our convertible notes have an aggregate fair value of approximately $2.3 million and would be categorized within Level 2 of the fair value hierarchy. Secured Contingent Payment Obligation The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the years ended December 31, 2021 and 2020, respectively (in thousands). 2021 2020Secured contingent payment obligation, beginning of year $ 33,057 $ 26,651Change in fair value 4,315 6,406Secured contingent payment obligation, end of year $ 37,372 $ 33,057 Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“Brickell”) under a February 2016 funding agreement, as amended from time to time (the “CPIA”). To date, we have received aggregate proceeds of $18 million in exchange for Brickell’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. No proceeds were received from Brickell in 2020 or 2021. To date, we have repaid an aggregate of $3.3 million under the CPIA from patent license and settlement proceeds. Brickell is entitled to priority payment of 100% of proceeds received by us, after reimbursement of out-of-pocket expenses and legal contingent fees, from all patent-related actions until such time that Brickell has been paid its minimum return. The minimum return is determined as a multiple of the funded amount that increases over time. The estimated minimum return due to Brickell was approximately $48.8 million and $42 million as of December 31, 2021 and 2020, respectively. In addition, Brickell is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the minimum return. Brickell holds a senior security interest in the majority of our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions. The security interest is enforceable by Brickell in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to Brickell, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without Brickell’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under the agreement. As of December 31, 2021, we are in compliance with our obligations under this agreement. In addition, in the event of a change in control of the Company, Brickell has the right to be paid its return as defined under the CPIA based on the transaction price for the change in control event. We have elected to measure our secured contingent payment obligation at its estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 10). The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved. Unsecured Contingent Payment Obligations The following table provides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the years ended December 31, 2021 and 2020, respectively (in thousands): 2021 2020Unsecured contingent payment obligations, beginning of period $ 5,222 $ -Reclassification of other liabilities - 1,003Issuance of contingent payment rights 412 2,258Change in fair value 57 1,961Unsecured contingent payment obligations, end of period $ 5,691 $ 5,222 Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder (“Termination Fee”) and (ii) contingent payment rights (“CPRs”) issued to accredited investors primarily in connection with equity financings. We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods.  The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved (see Note 10).The Termination Fee is a result of advances received under a letter agreement with a third-party funder of $0.4 million in 2019 and $0.6 million in 2020.  Based on the terms of the letter agreement, if a final funding arrangement was not executed by March 31, 2020, we would be obligated to pay, from future patent-related proceeds, an aggregate termination payment equal to five times the advances received, or approximately $5.0 million.  We did not consummate a funding agreement and accordingly the advances were recorded as an unsecured contingent payment obligation at March 31, 2020, when the Termination Fee obligation was incurred.  As of December 31, 2021, the estimated fair value of unsecured contingent payment obligations related to the Termination Fee is $2.6 million. The CPRs represent the estimated fair value of rights provided to accredited investors who purchased shares of our common stock in 2020 and 2021 and the fair value of a right issued to a third-party in connection with a service agreement during the year ended December 31, 2020 (see Note 13).  During the years ended December 31, 2021 and 2020, we received aggregate proceeds of $1.1 million and $3.8 million, respectively from the sale of common stock with contingent payment rights, of which approximately $0.4 million and $1.8 million, respectively was allocated to the CPRs.  In addition, on May 1, 2020, we amended certain March 2020 equity purchase agreements with accredited investors for the purchase of $0.9 million in common stock to add CPRs. This amendment resulted in a charge to expense of $0.4 million for the initial estimated fair value of the CPRs.  The terms of the CPRs provide that we will pay each investor an allocated portion of our net proceeds from patent-related actions, after taking into account fees and expenses payable to law firms representing us and amounts payable to Brickell.  The investors’ allocated portion of net proceeds will be determined by multiplying the net proceeds recovered by us (up to $10 million) by the quotient of such investors’ subscription amount divided by $10 million, up to an amount equal to each investor’s subscription amount, or an aggregate of $5.8 million.  As of December 31, 2021, the estimated fair value of our unsecured contingent payment obligations related to the CPRs is $3.1 million.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	10. FAIR VALUE MEASUREMENTS ASC 820, “Fair Value Measurements” establishes a fair value hierarchy that prioritizes the inputs to valuation methods used to measure fair value. The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices for identical assets or liabilities in active markets which we can accessLevel 2: Observable inputs other than those described in Level 1Level 3: Unobservable inputs The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2021 and 2020, segregated by classification within the fair value hierarchy (in thousands): Fair Value Measurements Total Quoted Prices in‎Active Markets‎(Level 1) Significant Other‎Observable‎Inputs (Level 2) Significant‎Unobservable‎Inputs (Level 3)December 31, 2021: Liabilities: Secured contingent payment obligation$ 37,372 $ - $ - $ 37,372Unsecured contingent payment obligations 5,691 - - 5,691 December 31, 2020: Liabilities: Secured contingent payment obligation 33,057 - - 33,057Unsecured contingent payment obligations 5,222 - - 5,222  For the years ended December 31, 2021 and 2020, respectively, we had no transfers of assets or liabilities between the levels of the hierarchy. The fair values of our secured and unsecured contingent payment obligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate.  We used a risk-adjusted discount rate of 14.85% at December 31, 2021, based on a risk-free rate of 0.85% as adjusted by 8% for credit risk and 6% for litigation inherent risk. The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at December 31, 2021, including the lowest and highest undiscounted payout scenarios as well as a weighted average payout scenario based on relative undiscounted fair value of each cash flow scenario. Secured Contingent Payment Obligation Unsecured Contingent Payment ObligationsUnobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $0.0 $51.8 $79.6 $0.0 $8.1 $10.8Duration (in years) 0.5 2.3 3.5 1.5 2.5 3.5Estimated probabilities 7% 23% 25% 25% 25% 25% We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations.  Changes in any of these Level 3 inputs could result in a significantly higher or lower fair value measurement

Income Taxes And Tax Status

Income Taxes And Tax Status	12 Months Ended
	Dec. 31, 2021
Income Taxes And Tax Status [Abstract]
Income Taxes And Tax Status	11. INCOME TAXES AND TAX STATUS Our net losses before income taxes for the years ended December 31, 2021 and 2020 are from domestic operations as well as losses from our wholly-owned German subsidiary. We elected to treat our German subsidiary as a disregarded entity for purposes of income taxes and accordingly, the losses from our German subsidiary have been included in our operating results. No current or deferred tax provision or benefit was recorded in 2021 or 2020 as a result of current losses and fully deferred tax valuation allowances for all periods. We have recorded a valuation allowance to state our deferred tax assets at their estimated net realizable value due to the uncertainty related to realization of these assets through future taxable income. A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for each of the years ended December 31, 2021 and 2020, respectively are as follows (in thousands): 2021 2020Tax benefit at statutory rate$ (2,589) $ (4,111)State tax benefit (530) (842)Increase in valuation allowance 3,368 4,307Other (249) 646 $ - $ - Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2021 and 2020 (in thousands): 2021 2020Gross deferred tax assets: Net operating loss carry-forward$ 78,600 $ 80,848Research and development credit carry-forward 6,028 6,603Stock compensation 356 122Patents and other 1,470 1,466Contingent payment obligations 6,341 5,235Fixed assets 53 54Accrued liabilities - 64Lease liabilities 38 77 92,886 94,469Less valuation allowance (92,886) (94,245) - 224Gross deferred tax liabilities: Convertible debt - (224) - (224)Net deferred tax asset$ - $ - Upon adoption of ASU 2020-06 on January 1, 2021 (see “Convertible Notes” in Note 9), the difference between the financial accounting and tax bases, net of tax effect, of unrecognized tax benefit related to the beneficial conversion feature of convertible debt was eliminated. At December 31, 2021, we had cumulative net operating loss (“NOL”) carry-forwards for income tax purposes of $313.2 million, of which $276.6 million is subject to expiration in varying amounts from 2022 to 2037. At December 31, 2021, we also had research and development tax credit carryforwards of $6.0 million, which expire in varying amounts from 2022 through 2038. Our ability to benefit from the tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if there are ownership changes of more than 50%, as defined by Section 382 of the Internal Revenue Code of 1986 (“Section 382”). Under Section 382, an ownership change may limit the amount of NOL, capital loss and R&D credit carry-forwards that can be used annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.  We conduct a study annually of our ownership changes. Based on the results of our studies, we have determined that we do not have any ownership changes on or prior to December 31, 2021 which would result in limitations of our NOL, capital loss or R&D credit carry-forwards under Section 382. Uncertain Tax PositionsWe file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Germany.  We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined.  The periods subject to examination for those returns are the 2002 through 2021 tax years.  The following table provides a reconciliation of our unrecognized tax benefits due to uncertain tax positions for the years ended December 31, 2021 and 2020, respectively (in thousands): 2021 2020Unrecognized tax benefits – beginning of year$ 927 $ 927Reduction as a result of lapse of statute of limitations (274) -Unrecognized tax benefits – end of year$ 653 $ 927 Future changes in the unrecognized tax benefit will have no impact on the effective tax rate so long as we maintain a full valuation allowance. Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense.  We do not have any accrued interest or penalties associated with any unrecognized tax benefits.  For the years ended December 31, 2021 and 2020, we did not incur any income tax-related interest income, expense or penalties.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12. COMMITMENTS AND CONTINGENCIES Legal ProceedingsFrom time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) and in the Federal Patent Court in Germany in an attempt to invalidate certain of our patent claims. The majority of our litigation, including our PTAB proceedings, is being paid for through contingency fee arrangements with our litigation counsel as well as third-party litigation financing. In general, litigation counsel is entitled to recoup on a priority basis, from litigation proceeds, any out-of-pocket expenses incurred. Following reimbursement of out-of-pocket expenses, litigation counsel is generally entitled to a percentage of remaining proceeds based on the terms of the specific arrangement between us, counsel and our third-party litigation funder. We were liable for costs assessed on infringement and validity cases in Germany in which we did not prevail. A portion of this liability was covered by bonds posted in Germany. As of December 31, 2021, our bonds have been fully released and all outstanding statutory court costs have been satisfied in full. We have no remaining litigation or related liabilities in Germany. ParkerVision v. Qualcomm (Middle District of Florida)We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “Qualcomm”) seeking approximately $1.3 billion in damages for infringement of four of our patents (the “Qualcomm Action”).  HTC Corporation and HTC America, Inc. (collectively “HTC”) were also defendants in this case but we voluntarily dismissed our claims against HTC and HTC dismissed their related counter-claims against us in October 2020.  Qualcomm has pending counterclaims against us for non-infringement and invalidity for all patents in the case.  The case was filed in May 2014 and stayed in February 2016 pending decisions in other cases, including the appeal of a PTAB proceeding with regard to U.S. patent 6,091,940 (“the ‘940 Patent”) asserted in this case.  In March 2017, the PTAB ruled in our favor on three of the six petitions (the method claims), ruled in Qualcomm’s favor on two of the six petitions (the apparatus claims) and issued a split decision on the claims covered in the sixth petition.  In September 2018, the Federal Circuit upheld the PTAB’s decision with regard to the ‘940 Patent and, in January 2019, the court lifted the stay in this case.  In July 2019, the court issued an order that granted our proposed selection of patent claims from four asserted patents, including the ‘940 Patent, and denied Qualcomm’s request to limit the claims and patents. The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay.  In September 2019, Qualcomm filed a motion for partial summary judgement in an attempt to exclude certain patents from the case, including the ‘940 Patent.  The court denied this motion in January 2020.   In April 2020, the court issued its claim construction order in which the court adopted our proposed construction for seven of the ten disputed terms and adopted slightly modified versions of our proposed construction for the remaining terms.  Due to the impact of COVID-19, a number of the scheduled deadlines in this case were moved including the trial commencement date which was rescheduled from December 2020 to May 2021. In October 2020, our damages expert submitted a report supporting our damages ask of $1.3 billion for Qualcomm’s unauthorized use of our technology. Such amount excludes additional amounts requested by us for interest and enhanced damages for willful infringement.  Ultimately, the amount of damages, if any, will be determined by the court.  Discovery was expected to close in December 2020; however, the court allowed us to designate a substitute expert due to medical issues with one of our experts in the case. Accordingly, the close of discovery was delayed until January 2021.  As a result of these delays, the court rescheduled the trial commencement date from May 3, 2021 to July 6, 2021.  In March 2021, the court further delayed the trial date citing backlog due to the pandemic, among other factors.  A new trial date has not yet been set.  Fact and expert discovery in this case are closed, expert reports have been submitted, and summary judgement and Daubert briefings have been completed by the parties.  Joint pre-trial statements were submitted in May 2021. In March 2021, the court granted Qualcomm’s motion to strike certain of our 2020 infringement contentions.  We filed a motion to clarify the court’s order and in July 2021, based on the court’s response to our motion to clarify, we filed a joint motion for entry of a judgement of non-infringement of our Patent No. 7,865,177 (“the ‘177 Patent”), subject to appeal.  A number of outstanding motions are pending decisions by the court.  In January 2022, the court held a hearing to allow the parties to present their respective positions on three outstanding motions. The court indicated that upon its ruling on these motions, a pre-trial conference will be scheduled and a trial date set. On March 9, 2022, the court ruled with respect to one of these motions granting Qualcomm’s motion to strike and exclude opinions regarding the alleged infringement and validity issues. This court order prevents the presentation of infringement and validity opinions by both of our experts at trial. In addition, on March 22, 2022, the court issued an order granting Qualcomm’s motion for summary judgment ruling that Qualcomm does not infringe the remaining three patents in this case. This is a final judgment and the next step is an appeal of both the March 22, 2022 and the March 9, 2022 rulings (see Note 17). We are represented in this case on a full contingency fee basis. ParkerVision v. Apple and Qualcomm (Middle District of Florida)In December 2015, we filed a patent infringement complaint in the Middle District of Florida against Apple, LG, Samsung and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of a corresponding case filed at the International Trade Commission (“ITC”). In July 2016, we entered into a patent license and settlement agreement with Samsung and, as a result, Samsung was dismissed from the district court action. In March 2017, we filed a motion to terminate the ITC proceedings and a corresponding motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case and re-filed our claims against LG in the District of New Jersey (see ParkerVision v. LG below).  Also in July 2017, Qualcomm filed a motion to change venue to the Southern District of California, and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case. A claim construction hearing was held on August 31, 2018. In July 2019, the court issued its claim construction order in which the court adopted our proposed claim construction for two of the six disputed terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied a motion filed by Apple for summary judgment.  Fact discovery has closed in this case and a jury trial was scheduled to begin in August 2020.  In March 2020, as a result of the impact of COVID-19, the parties filed a motion requesting an extension of certain deadlines in the case. In April 2020, the court stayed this proceeding pending the outcome of the Qualcomm Action.   ParkerVision v. LG (District of New Jersey)In July 2017, we filed a patent infringement complaint in the District of New Jersey against LG for the alleged infringement of the same patents previously asserted against LG in the Middle District of Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in the Middle District of Florida and re-file in New Jersey as a result of a Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case. ParkerVision v. Intel (Western District of Texas)In February 2020, we filed a patent infringement complaint in the Western District of Texas against Intel Corporation (“Intel”) alleging infringement of eight of our patents. The complaint was amended in May 2020 to add two additional patents. In June 2020, we requested that one of the patents be dropped from this case and filed a second case in the Western District of Texas that included this dismissed patent (see ParkerVision v. Intel II below). Intel’s response to our complaint was filed in June 2020 denying infringement and claiming invalidity of the patents. Intel also filed a motion to transfer venue which the court denied. In July 2020 and September 2020, Intel filed IPR petitions against two of the patents in this case and in January 2021, the PTAB instituted proceedings with regard to these two petitions (see Intel v. ParkerVision (PTAB) below). The court issued its claim construction ruling in January 2021 in which the majority of the disputed claim terms were decided in our favor. The case was scheduled for trial beginning February 7, 2022. In April 2021, we filed an amended complaint to include additional Intel chips and products, including WiFi devices, to the complaint. The court suggested that, given the number of patents at issue, the case would be separated into two trials and, as a result of the added products, the first trial date was moved to June 2022. In January 2022, the PTAB issued its ruling on the IPRs (see Intel v. ParkerVision (PTAB) below). In February 2022, the parties filed a joint motion with respect to both Intel cases whereby the first case would be narrowed to six total patents asserted against Intel cellular products. These same six patents would be also asserted in the second Intel case, along with one additional patent from the second case, against Intel WiFi and Bluetooth products. As a result of the restructuring of the two cases, the trial date was moved to October 2022. In March 2022, due to discovery delays, the court agreed to move the trial commencement date to December 5, 2022. Discovery is ongoing in this case. We are represented in this case on a full contingency fee basis. ParkerVision v. Intel II (Western District of Texas)In June 2020, to reduce the number of claims in ParkerVision v. Intel, we filed a second patent infringement complaint in the Western District of Texas against Intel that included a single patent that we voluntarily dismissed from the original case.  In July 2020, we amended our complaint adding two more patents to the case.  Intel responded to the complaint denying infringement and claiming invalidity of the patents. In January 2021, Intel filed a petition for IPR against one of the patents in this case and in July 2021, the PTAB instituted proceedings with regard to this petition (see Intel v. ParkerVision (PTAB) below). We filed an amended complaint in 2021 adding Intel WiFi and Bluetooth products to the case. Two claim construction hearings were held in June 2021 and July 2021 and the court’s claim construction ruling was largely decided in our favor.  The case was scheduled for trial in October 2022. In February 2022, the parties filed a joint motion which provided that the Intel II case would assert the same six patents from the first Intel case, provided none of the patents were invalidated in the first case, as well as one additional patent, depending on the outcome of the pending IPR proceeding. As a result of the restructuring of the cases, the trial date for this case is rescheduled for May 2023 although this date may change in lieu of the schedule changes in the first Intel case.  We are represented in this case on a full contingency fee basis. Additional Patent Infringement Cases – Western District of TexasParkerVision filed a number of additional patent cases in the Western District of Texas in September and October 2020 including cases against (i) TCL Industries Holdings Co., Ltd, a Chinese company, TCL Electronics Holdings Ltd., Shenzhen TCL New Technology Co., Ltd, TCL King Electrical Appliances (Huizhou) Co., Ltd., TCL Moka Int’l Ltd. and TCL Moka Manufacturing S.A. DE C.V. (collectively “TCL”), (ii) Hisense Co., Ltd. and Hisense Visual Technology Co., Ltd (collectively “Hisense”), a Chinese company, (iii) Buffalo Inc., a Japanese company (“Buffalo”) and (iv) Zyxel Communications Corporation, a Chinese multinational electronics company headquartered in Taiwan, (“Zyxel”).  Each case alleges infringement of the same ten patents by products that incorporate modules containing certain WiFi chips manufactured by Realtek and/or MediaTek.  Each of the defendants have filed responses denying infringement and claiming invalidity of the patents, among other defenses. In May 2021, we filed a patent infringement case against LG Electronics (“LGE”), a South Korean company, in the Western District of Texas alleging infringement of the same ten patents. A second action was filed against Hisense in June 2021 in the Western District of Texas for infringement of two additional patents. In September 2021, we dismissed the cases against Buffalo and Zyxel following satisfaction of the parties’ obligations under settlement and license agreements entered into in May 2021 and September 2021, respectively. In May 2021, TCL and Hisense filed petitions for IPR against two of the ten patents asserted against them, including U.S. Patent 7,110,444 (“the ‘444 Patent”) which was challenged by Intel (see TCL, et. al. v. ParkerVision (PTAB) below). In December 2021, LGE filed nearly identical petitions for IPR against the same two patents along with a joinder motion requesting to join the existing petitions. The court held a combined Markman hearing on October 27, 2021 for the cases against Hisense and TCL. The court issued its claim construction recommendations on October 29, 2021, in which nearly all of the claim terms were decided in our favor. The Hisense and TCL cases currently have a trial date scheduled for December 12, 2022. The LGE case currently has a claim construction hearing scheduled for April 25, 2022 and a trial scheduled to commence on April 24, 2023. We are represented in each of these cases on a full contingency fee basis. Intel v. ParkerVision (PTAB)Intel filed petitions for Inter Partes Review (IPR) against U.S. patent 7,539,474 (“the ‘474 Patent”), and the ‘444 Patent which were both asserted in ParkerVision v. Intel. Intel also filed a petition for IPR against U.S. patent 8,190,108 (“the ‘108 patent”) which is asserted in ParkerVision v. Intel II.  In January 2021, the PTAB issued its decision to institute IPR proceedings for the ‘444 Patent and the ‘474 Patent. An oral hearing was held on November 1, 2021 and final decisions from the PTAB on the ‘474 Patent and the ‘444 Patent were issued in January 2022. The PTAB ruled against us with respect to the single challenged claim of the ‘444 Patent and ruled in our favor with respect to the seven challenged claims of the ‘474 Patent. The ‘444 Patent has subsequently been excluded from the narrowed claims asserted in ParkerVision v. Intel. In July 2021, the PTAB issued its decision to institute IPR proceedings for the ‘108 Patent. We filed our response to this petition in October 2021 and an oral hearing is scheduled for April 2022. A final decision from the PTAB with respect to the ‘108 Patent is expected by July 2022. Depending on the PTAB’s ruling with respect to the ‘108 Patent, we have the option to include or exclude this patent from the patents being asserted in the Intel II case. TCL, et. al. v. ParkerVision (PTAB)In May 2021, TCL, along with Hisense, filed petitions for Inter Partes Review (“IPR”) against U.S. patent 7,292,835 (“the ‘835 Patent”) and the ‘444 Patent, both of which are asserted in the infringement cases against these parties in the Western District of Texas. In November 2021, the PTAB issued its decision to implement IPR proceedings for these two patents. In December 2021, LGE filed nearly identical petitions against the same two patents along with a joinder motion requesting to join the existing petitions filed by TCL and Hisense. Oral hearings are scheduled for these IPRs in September 2022 with a final decision expected in November 2022.

Stock Authorization and Issuanc

Stock Authorization and Issuance	12 Months Ended
	Dec. 31, 2021
Stock Authorization and Issuance [Abstract]
Stock Authorization and Issuance	13. STOCK AUTHORIZATION AND ISSUANCE  Preferred StockWe have 15 million shares of preferred stock authorized for issuance at the direction of our board of directors (the “Board”). On November 17, 2005, our Board designated 0.1 million shares of authorized preferred stock as the Series E Preferred Stock in conjunction with its adoption of a Shareholder Protection Rights Agreement. As of December 31, 2021, we had no outstanding preferred stock. Common Stock We have 150 million shares of common stock authorized for issuance as of December 31, 2021. Our shareholders approved amendments to our articles of incorporation in July 2020 increasing the number of our authorized shares of common stock from 110 million to 140 million shares and in September 2021 increasing the number of our authorized shares of common stock from 140 million to 150 million shares. As of December 31, 2021, we have 33.6 million shares reserved for issuance under outstanding warrants and options and 20.2 million shares reserved for issuance upon conversion of our outstanding convertible notes. In addition, we have 2.0 million shares reserved for future issuance under equity compensation plans and 3.2 million shares reserved for future issuance upon payment of interest in-kind on our convertible notes. ‎ Stock and Warrant Issuances – Equity Based FinancingsThe following table presents a summary of completed equity-based financing transactions for the years ended December 31, 2020 and 2021 (in thousands, except for per share amounts):The following table presents a summary of completed equity-based financing transactions for the years ended December 31, 2020 and 2021 (in thousands, except for per share amounts): DateTransaction # of Common Shares/ Units Sold Average Price per Share/ Unit # of Warrants Issued‎(in 000’s) Average Exercise Price per Warrant Net Proceeds (1)January 2020Private placement of common stock 1,335 $0.13 - - $ 177February 2020Warrant amendment - - 5,000 $0.74 $ -March 2020Private placement of common stock, amended to add CPR 2,571 $0.35 - - $ 900April 2020 to December 2020Private placement of common stock with CPRs 10,858 $0.35 - - $ 3,724January 2021Private placement of common stock with CPRs 2,976 $0.35 - - $ 1,040March 2021Private placement of common stock with warrants 3,231 $1.29 1,619 $1.75 $ 4,156December 2021Private placement of common stock with warrants 1,053 $0.95 526 $1.00 $ 1,000 (1)After deduction of applicable offering costs. Net proceeds are inclusive of the value of the CPRs that are classified as long-term debt (see Note 9). Private Placements In January 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 1,169,232 shares of our common stock at a price of $0.13 per share and 166,667 shares of our common stock at $0.15 per share for aggregate proceeds of approximately $0.2 million. In March 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 2,571,432 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $0.9 million.   The securities purchase agreements for the March 2020 transactions were amended on May 1, 2020,  in order to add a contingent payment right whereby we will pay each investor an allocated portion of our share of proceeds from patent-related actions, after taking into account fees and expenses payable to law firms representing us and amounts payable to Brickell, up to an amount equal to the investors’ aggregate subscription amount, or $0.9 million (see “Unsecured Contingent Payment Obligations” in Note 9). The shares were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-237762). From April to December 2020, we entered into securities purchase agreements with accredited investors for an aggregate of 10,857,876 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $3.8 million.  The securities purchase agreements include contingent payment rights. Approximately $1.8 million of the proceeds were allocated to unsecured contingent payment obligations based on the initial fair value estimate of the CPRs (see “Unsecured Contingent Payment Obligations” in Note 9).  The shares sold from April to August, totaling 5,871,584 shares, were registered for resale on a registration statement that was declared effective on September 2, 2020 (File No. 333-248242). The shares sold from August to December, totaling 4,986,292 shares, were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217). In January 2021, we entered into securities purchase agreements with accredited investors for the sale of an aggregate of 2,976,430 shares of our common stock at a price of $0.35 per share for aggregate proceeds of $1.0 million. The securities purchase agreements include contingent payment rights. Approximately $0.4 million of the proceeds were allocated to unsecured contingent payment obligations based on the initial fair value estimate of the CPRs (see “Unsecured Contingent Payment Obligations” in Note 9). The shares were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217). In March 2021, we entered into securities purchase agreements with accredited investors for the sale of 3,230,942 shares of our common stock and 1,619,289 warrants at a price of $1.29 per common share for aggregate proceeds of approximately $4.2 million. The warrants have an exercise price of $1.75 per share and expire in March 2026. The shares, including the shares underlying the warrants, were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217). We used $3.0 million of the proceeds from this transaction to satisfy our obligations to Mintz (see “Secured Note Payable” in Note 9). In December 2021, we entered into a securities purchase agreement with an accredited investor for the sale of 1,052,631 shares of our common stock and 526,315 warrants at a price of $0.95 per common share for aggregate proceeds of $1.0 million. The warrants have an exercise price of $1.00 per share and expire in December 2026. The shares, including the shares underlying the warrants, were registered for resale on a registration statement that was declared effective on January 24, 2022 (File No. 333-262147). Warrant Amendment On February 28, 2020, we entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with Aspire Capital Fund, LLC (“Aspire”), with respect to warrants issued in July and September 2018 (the “2018 Warrants”) that are exercisable, collectively, into 5,000,000 shares of our common stock.  The Warrant Amendment Agreement provided for a reduction in the exercise price for the 2018 Warrants from $0.74 to $0.35 per share and the issuance of a new warrant for the purchase of 5,000,000 shares of our common stock at an exercise price of $0.74 per share (“New Aspire Warrant”).  The New Aspire Warrant expires February 28, 2025 and is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and upon any distributions of assets to our stockholders.  The New Aspire Warrant contains provisions that prohibit exercise if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. The holder of the New Aspire Warrant may increase (up to 19.99%) or decrease this percentage by providing at least 61 days’ prior notice to the Company. In the event of certain corporate transactions, the holder of the New Aspire Warrant will be entitled to receive, upon exercise of such New Aspire Warrant, the kind and amount of securities, cash or other property that the holder would have received had they exercised the New Aspire Warrant immediately prior to such transaction. The New Aspire Warrant does not contain voting rights or any of the other rights or privileges as a holder of our common stock.We recognized $1.78 million of non-cash warrant expense in connection with the Warrant Amendment Agreement based on the difference between the Black-Scholes value of the warrants immediately before and after the amendment.  The Warrant Amendment Agreement added a call provision to the 2018 Warrants whereby we could, after December 31, 2020, call for cancellation of all or any portion of the 2018 Warrants for which an exercise notice has not yet been received, in exchange for consideration equal to $0.001 per warrant share and subject to certain conditions.  All other terms of the 2018 Warrants remained unchanged, including the original expiration dates of July and September 2023.   The shares underlying the New Aspire Warrant were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-237762).  The shares underlying the 2018 Warrants are currently registered for resale pursuant to a registration statement on Form S-1 (File No. 333-226738). Upon execution of the Warrant Amendment Agreement, Aspire exercised 1,430,000 shares of the 2018 Warrants for aggregate proceeds to us of $0.5 million.  For the years ended December 31, 2021 and 2020, Aspire exercised 500,000 and 3,070,000 shares of the 2018 Warrants for aggregate additional proceeds to us of approximately $0.2 and $1.1 million, respectively.   Stock and Warrant Issuances – Payment for ServicesOn February 10, 2020, we entered into a business consulting and retention agreement with Chelsea Investor Relations (“Chelsea”) to provide business advisory services to us.  As consideration for services to be provided under the 24-month term of the consulting agreement, we issued 500,000 shares of unregistered common stock in exchange for a nonrefundable retainer for services valued at approximately $0.15 million.  The value of the stock issued is being recognized as consulting expense over the term of the agreement. The shares were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-237762). In January 2021, we amended the agreement with Chelsea to increase the compensation for services over the remaining term and to extend the term of the agreement through February 2024.  As consideration for the amended agreement, we issued 500,000 shares of unregistered common stock in exchange for a nonrefundable retainer for services valued at approximately $0.33 million.  The value of the stock issued is being recognized as consulting expense over the term of the agreement. The shares were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217). On March 16, 2020, we entered into an agreement with Tailwinds Research Group LLC (“Tailwinds”) to provide digital marketing services to us.  As consideration for services to be provided under the twelve-month term of the agreement, we issued warrants for the purchase up to 200,000 shares of our common stock with an exercise price of $1.00 per share in exchange for a nonrefundable retainer for services, valued using the Black-Scholes method, at approximately $0.06 million.  The value of the warrants was recognized as expense over the twelve-month term of the agreement.  The Tailwinds warrants are exercisable immediately after issuance, expire March 16, 2023, and are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.  The shares underlying the warrant were registered for resale on a registration statement that was declared effective on April 28, 2020 (File No. 333-237762). On May 22, 2020, we entered into an agreement with Intro-Act to provide research and shareholder relations services. As consideration for services under the agreement, we issued 50,000 shares of unregistered common stock on each of July 14, 2020, October 30, 2020, January 12, 2021 and April 6, 2021 with an aggregate value of approximately $0.05 million for the year ended December 31, 2020 and $0.1 million for the year ended December 31, 2021. In June 2021, we extended our agreement with Intro-Act and issued 100,000 shares of unregistered common stock valued at approximately $0.12 million as consideration for services to be provided over the twelve-month extended term of the agreement. The value of the shares will be recognized as consulting expense over the term of the agreement. We are not obligated to register the shares for resale. On June 8, 2020, we entered into an agreement with a third party to provide media advisory services.  As consideration for services provided under the term of the agreement, which extended through December 31, 2020, we issued 30,000 shares of unregistered common stock for a nonrefundable retainer for services valued at approximately $0.01 million.  The value of the stock issued was recognized as a consulting expense over the term of the agreement.  The shares were registered for resale on a registration statement that was declared effective on April 26, 2021 (File No. 333-255217). On October 30, 2020, we entered into a consulting services agreement with a third-party to provide shareholder relations services. As consideration for services provided under the twelve-month term of the agreement, we issued 70,000 shares of unregistered common stock for a non-refundable retainer for services valued at approximately $0.02 million. The agreement included a CPR to receive up to $0.02 million from patent-related proceeds. The CPR was recorded as debt at its estimated fair value of approximately $0.1 million (see “Unsecured Contingent Payment Obligations” in Note 9). In April 2021, we amended the consulting services agreement and extended the term through December 31, 2021. We issued 35,000 shares of our unregistered common stock valued at approximately $0.04 million as compensation over the remaining term of the agreement. The value of the shares issued were recognized as consulting expense over the term of the agreement.   In addition, from time to time, we issue restricted stock awards under our approved equity plans to third party consultants as share-based compensation. During the year ended December 31, 2021, we issued 217,143 RSAs valued at $0.3 million under our 2019 long-term incentive equity plan to nonemployees as compensation under consulting agreements (see Note 14). Common Stock WarrantsAs of December 31, 2021 and 2020, we had outstanding warrants for the purchase of up to 10.3 million shares and 12.9 million shares of our common stock, respectively. The estimated grant date fair value of these warrants of $3.2 million and $1.7 million at December 31, 2021 and 2020, respectively, is included in shareholders’ deficit in our consolidated balance sheets. As of December 31, 2021, our outstanding warrants have an average exercise price of $0.75 per share and a weighted average remaining life of approximately three years. Shareholder Protection Rights AgreementOn November 20, 2020, we adopted a second amendment to our Shareholder Protection Rights Agreement (“Rights Agreement”) dated November 21, 2005, as amended. The amendment extends the expiration date of the Rights Agreement from November 20, 2020 to November 20, 2023 and decreases the exercise price of the rights from $14.50 to $8.54. The Rights Agreement provided for the issuance, on November 29, 2005, as a dividend, rights to acquire fractional shares of Series E Preferred Stock. We did not assign any value to the dividend, as the value of these rights is not believed to be objectively determinable. The principal objective of the Rights Agreement is to cause someone interested in acquiring us to negotiate with our Board rather than launch an unsolicited or hostile bid. The Rights Agreement subjects a potential acquirer to substantial voting and economic dilution. Each share of common stock issued by ParkerVision will include an attached right. The rights initially are not exercisable and trade with the common stock of ParkerVision. In the future, the rights may become exchangeable for shares of Series E Preferred Stock with various provisions that may discourage a takeover bid. Additionally, the rights have what are known as “flip-in” and “flip-over” provisions that could make any acquisition of us more costly to the potential acquirer. The rights may separate from the common stock following the acquisition of 15% or more of the outstanding shares of common stock by an acquiring person. Upon separation, the holder of the rights may exercise their right at an exercise price of $8.54 per right (the “Exercise Price”), subject to adjustment and payable in cash. Upon payment of the Exercise Price, the holder of the right will receive from us that number of shares of common stock having an aggregate market price equal to twice the Exercise Price, as adjusted. The Rights Agreement also has a flip over provision allowing the holder to purchase that number of shares of common/voting equity of a successor entity, if we are not the surviving corporation in a business combination, at an aggregate market price equal to twice the Exercise Price. We have the right to substitute for any of our shares of common stock that we are obligated to issue, shares of Series E Preferred Stock at a ratio of one ten-thousandth of a share of Series E Preferred Stock for each share of common stock. The Series E Preferred Stock, if and when issued, will have quarterly cumulative dividend rights payable when and as declared by the Board, liquidation, dissolution and winding up preferences, voting rights and will rank junior to other securities of ParkerVision unless otherwise determined by the Board. The rights may be redeemed upon approval of the Board at a redemption price of $0.01. As of December 31, 2021, there are no Series E preferred shares outstanding.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-Based Compensation [Abstract]
Share-Based Compensation	14. SHARE-BASED COMPENSATION   For the years ended December 31, 2021 and 2020 we recognized share-based compensation expense of approximately $3.3 million and $1.2 million, respectively. Share-based compensation is included in selling, general, and administrative expenses in our consolidated statements of comprehensive loss. From time to time, we issue fully vested share-based compensation awards to third parties as prepaid retainers for services over a specified period. The cost of these awards is recorded as a prepaid asset and expensed to selling, general and administrative expense over the service period (see Note 4). As of December 31, 2021, there was $3.0 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. That cost is expected to be recognized over a weighted-average period of approximately 1.0 year. Stock Incentive Plans2019 Long-Term Incentive Equity PlanWe adopted a long-term incentive equity plan in August 2019 that provides for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 12.0 million shares of common stock (the “2019 Plan”). The 2019 Plan provides for benefits in the form of nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2019 Plan become available for reissuance. The plan provides that non-employee directors may not be granted awards that exceed the lesser of 1.0 million shares or $175,000 in value, calculated based on grant-date fair value. In January 2021, the Board amended the 2019 Plan to increase the number of shares of common stock reserved for issuance under the 2019 Plan from 12 million to 27 million shares. At December 31, 2021, 1,897,857 shares of common stock were available for future grants under the 2019 Plan. 2011 Long-Term Incentive Equity PlanWe adopted a long-term incentive equity plan in September 2011 that, as amended in 2014, 2016 and 2017, provides for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 3.0 million shares of common stock (the “2011 Plan”). The 2011 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2011 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 150,000 shares in any calendar year. At December 31, 2021, 61,302 shares of common stock were available for future grants under the 2011 Plan. 2008 Equity Incentive PlanWe adopted an equity incentive plan in August 2008 (the “2008 Plan”). The 2008 Plan provides for the grant of stock-based awards to employees (excluding named executives), directors and consultants, not to exceed 50,000 shares of common stock. The 2008 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2008 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 5,000 shares in any calendar year. At December 31, 2021, 20,473 shares of common stock were available for future grants under the 2008 Plan. Restricted Stock AwardsRSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested. Restricted Stock UnitsRSUs are issued as incentive compensation to executives, employees, and non-employee directors. Each RSU represents a right to one share of our common stock, upon vesting. The RSUs are not entitled to voting rights or dividends, if any, until vested. RSUs generally vest over a one to three year period for employee awards and a one year period for non-employee director awards. The fair value of RSUs is generally based on the closing price of our common stock on the date of grant and is amortized to share-based compensation expense over the estimated life of the award, generally the vesting period. RSAs and RSUs The following table presents a summary of RSA and RSU activity under the 2008, 2011, and 2019 Plans (collectively, the “Stock Plans”) as of December 31, 2021 (shares in thousands): Non-vested Shares Shares Weighted-Average‎Grant Date Fair ValueNon-vested at beginning of year 187 $ 0.33Granted 217 1.34Vested (404) 0.87Forfeited - -Non-vested at end of year - $ - The awards granted under the Stock Plans in 2021 were all RSAs awarded to non-employees as compensation in connection with consulting agreements. The total fair value of RSAs and RSUs vested under the Stock Plans for the year ended December 31, 2021 was approximately $0.6 million. Stock OptionsStock options are issued as incentive compensation to executives, employees and non-employee directors. Stock options are generally granted with exercise prices at or above fair market value of the underlying shares at the date of grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans. The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2021 (shares in thousands): Shares Weighted-‎Average‎Exercise Price Weighted-Average‎Remaining‎Contractual Term Aggregate‎Intrinsic‎Value ($)Outstanding at beginning of year 12,240 $ 0.28 Granted 13,040 0.54 Exercised (2,029) 0.17 Forfeited/Expired (36) 11.18 Outstanding at end of year 23,215 0.42 4.2 years $ 11,988Vested at end of year 16,676 $ 0.37 4.3 years $ 9,503 In January 2021, the Board awarded 11.9 million nonqualified stock options to executives and other key employees and an aggregate of 1.1 million nonqualified stock options to non-employee directors under the 2019 Plan. The options are exercisable at $0.54 per share, vest in eight equal quarterly installments commencing March 31, 2021, and expire on January 11, 2026. The weighted average per share fair value of options granted during the years ended December 31, 2021 and 2020 was $0.46 and $0.27, respectively. The total fair value of option shares vested was $3.4 million and $0.9 million for the year ended December 31, 2021 and 2020, respectively. The fair value of option grants under the Stock Plans for the years ended December 31, 2021 and 2020, respectively, was estimated using the Black-Scholes option-pricing model with the following assumptions: Year ended December 31, 2021 2020Expected option term 14 years 5 yearsExpected volatility factor 2141.1% 127.4% to 135.3%Risk-free interest rate 30.36% 0.33% to 1.63%Expected annual dividend yield0% 0% 1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant.3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date. Options by Price RangeThe options outstanding at December 31, 2021 under all plans have exercise price ranges, weighted average contractual lives, and weighted average exercise prices as follows (weighted average lives in years and shares in thousands): Options Outstanding Options VestedRange of Exercise Prices Number Outstanding at December 31, 2021 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2021 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life$0.171 - $0.33 9,289 $ 0.18 4.6 9,289 $ 0.18 4.6$0.50 - $0.75 13,553 0.54 4.0 7,014 0.54 4.0$1.98 - $2.97 373 2.02 2.5 373 2.02 2.5 23,215 $ 0.42 4.2 16,676 $ 0.37 4.3 We issue new shares of our common stock upon exercise of options or vesting of RSUs or RSAs under the Stock Plans. The shares underlying the Stock Plans are registered. Cash received from option exercises for the year ended December 31, 2021, was $0.3 million. We had no option exercises for the year ended December 31, 2020.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	15. RELATED PARTY TRANSACTIONS We paid approximately $0.1 million and $0.01 million in 2021 and 2020, respectively, for patent-related legal services to SKGF, of which Robert Sterne, one of our directors since September 2006, is a partner. In addition, we paid approximately $0.1 million in both 2021 and 2020 for principal and interest on the SKGF Note (refer to “Note Payable to a Related Party” included in Note 9). The SKGF Note has an outstanding balance, including accrued interest, of approximately $0.7 million at December 31, 2021. In January 2020, we issued 500,000 in unregistered shares of our common stock as an in-kind payment of approximately $0.08 million in outstanding amounts payable to Stacie Wilf, sister to Jeffrey Parker.

Concentrations Of Credit Risk

Concentrations Of Credit Risk	12 Months Ended
	Dec. 31, 2021
Concentrations Of Credit Risk [Abstract]
Concentrations Of Credit Risk	16. CONCENTRATIONS OF CREDIT RISK Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may exceed the balance insured by the F.D.I.C.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	17. SUBSEQUENT EVENTS On March 22, 2022, the United States District Court in the Middle District of Florida (Orlando Division) issued an order granting Qualcomm’s motion for summary judgment ruling that Qualcomm does not infringe the three patents that are the subject of our infringement case against them. This ruling, which is a final determination of the district court, follows a March 9, 2022 order granting a Qualcomm motion to strike and exclude the opinions of our experts regarding the alleged infringement and validity issues. We intend to appeal both of these decisions. See ParkerVision v. Qualcomm (Middle District of Florida) included in Note 12 for a complete discussion of these legal proceedings. In February 2022, our two patent infringement cases against Intel in the Western District of Texas were reconfigured whereby the first case would assert an aggregate of six patents against Intel cellular products and the second case would assert the same six patents along with a seventh patent against Intel WiFi and Bluetooth products. As a result of the restructuring of the cases, the trial date for the first Intel case was moved from June 2022 to October 24, 2022. In March 2022, as a result of discovery delays, the trial date was moved to a start date of December 5, 2022. The second case against Intel is currently scheduled for trial commencing in May 2023, however that date may change in lieu of the revised schedule in the first Intel case. See ParkerVision v. Intel (Western District of Texas) and ParkerVision v. Intel II (Western District of Texas) included in Note 12 for a complete discussion of these legal proceedings. In January 2022, the Patent Trial and Appeal Board (“PTAB”) issued its final decisions on two Inter Partes Reviews (“IPRs”) filed by Intel against two of the patents asserted in the ParkerVision v. Intel infringement cases. The PTAB ruled in our favor with respect to the seven challenged claims of one of the two patents and ruled in Intel’s favor with respect to the one challenged claim of the second patent. We have one additional IPR filed by Intel against a patent asserted in our second case, and the PTAB is expected to issue its final decision in July 2022. Refer to Intel v. ParkerVision (PTAB) included in Note 12 for a complete discussion of these IPR proceedings.

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationOur consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our contingent payment obligations, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash and Cash Equivalents	Cash and Cash EquivalentsWe consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives: Manufacturing and office equipment5-7 yearsLeasehold improvementsShorter of useful life or remaining life of leaseFurniture and fixtures7 yearsComputer equipment and software3-5 years The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Intangible Assets	Intangible AssetsWe capitalize outside legal costs and agency filing fees incurred in connection with securing the rights to our intellectual property. Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists. As part of our ongoing patent maintenance program, we will, from time to time, abandon a particular patent if we determine fees to maintain the patent exceed its expected recoverability. The cost and accumulated amortization of abandoned intangible assets are removed from their respective accounts, and any resulting net loss is recognized in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Contingent Payment Obligations	Contingent Payment ObligationsWe have accounted for our secured and unsecured contingent payment obligations as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our payment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our contingent payment obligations at their estimated fair values in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured and unsecured contingent payment obligations falls within Level 3 in the fair value hierarchy, which involves significant estimates, and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 10). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligations.”
Leases	LeasesWe have accounted for our finance and operating leases in accordance with ASC 842, “Leases” which requires the recognition of lease right-of-use (“ROU”) assets and lease liabilities on our consolidated balance sheets for finance and operating leases with initial lease terms of more than 12 months. At inception of a lease, we determine if an arrangement contains a lease and whether that lease meets the classification criteria of a finance or operating lease. Some of our lease arrangements contain lease components (e.g. minimum rent payments) and non-lease components (e.g. services). For certain equipment leases, we account for lease and non-lease components separately based on a relative fair market value basis. For all other leases, we account for the lease and non-lease components (e.g. common area maintenance) on a combined basis. For operating leases with terms greater than 12 months, we record the ROU asset and lease obligation at the present value of lease payments over the term using the implicit interest rate, when readily available, or our incremental borrowing rate for collateralized debt based on information available at the lease commencement date. Certain of our leases include rental escalation clauses, renewal options and/or termination options that are factored into our determination of lease payments when it is reasonably certain that the option will be exercised. We do not recognize ROU assets and lease liabilities for leases with terms at inception of twelve months or less. Finance leases are included in property and equipment and other accrued expenses on the consolidated balance sheets. Finance leases are recorded as an asset and an obligation at an amount equal to the present value of the minimum lease payments during the lease term. Amortization expense and interest expense associated with finance leases are included in selling, general, and administrative expense and interest expense, respectively, on the consolidated statements of comprehensive loss. Refer to Note 8 for additional disclosures related to our leases.
Convertible Debt	Convertible DebtWe have issued debt that is convertible, at the holder’s option, into shares of our common stock at fixed conversion prices. Certain of the convertible notes were issued with conversion prices that were below market value of our common stock on the closing date resulting in a beneficial conversion feature which we recorded to equity with a corresponding discount to the debt that was amortized over the life of the notes as interest expense. Effective January 1, 2021, we adopted Accounting Standards Update (“ASU”) 2020-06 "Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."  This ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP.  Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features.  The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception.  The ASU also simplifies the diluted earnings per share calculation in certain areas.  For smaller reporting companies, the ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted for fiscal years beginning after December 15, 2020.  The ASU provides for a modified retrospective method of adoption whereby the guidance is applied to transactions outstanding at the beginning of the fiscal year of adoption with the cumulative effect of the change being recorded as an adjustment to beginning retained earnings. Adoption of ASU 2020-06 resulted in an increase to our long-term debt of approximately $0.8 million, a decrease in additional paid-in-capital of approximately $1.1 million, and an adjustment to our beginning accumulated deficit of $0.3 million resulting from the elimination of the previously recognized beneficial conversion feature as a debt discount.
Revenue Recognition	Revenue RecognitionWe account for revenue under ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. These steps include (1) identifying the contract with the customer, (2) identifying the performance obligations, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing revenue as the entity satisfies the performance obligation(s). Our revenue is derived from patent licensing and settlement agreements. We have an active monitoring and enforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third parties that utilize or have utilized our intellectual property without a license. As a result, we may receive payments as part of a settlement or in the form of court-awarded damages for a patent infringement dispute. The timing and amount of revenue recognized from each licensee depend upon a variety of factors, including the specific terms of each agreement and the nature of the deliverables and obligations. Such agreements are often complex and may include multiple performance obligations. These agreements can include performance obligations related to the settlement of past patent infringement liabilities, royalties on future covered products sold by licensees, access to a portfolio of technology as it exists at a point in time, and/or promises to provide technology updates to the portfolio during the term of the license. Refer to Note 3 for additional disclosures related to our revenue.
Cost of Sales	Cost of SalesCost of sales includes amortization of intangible assets directly linked with revenue generating licensing activities. Amortization expense for intangible assets that are not directly related to revenue generating licensing activities are included in selling, general, and administrative expenses in our consolidated statements of comprehensive loss.
Accounting for Share-Based Compensation	Accounting for Share-Based CompensationWe have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”). We calculate the fair value of share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.
Income Taxes	Income TaxesThe provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.
Loss per Common Share	Loss per Common ShareBasic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive. The number of shares underlying outstanding options, warrants, unvested RSUs, and convertible notes at December 31, 2021 and 2020 were as follows (in thousands): 2021 2020Options outstanding 23,215 12,240Warrants outstanding 10,346 12,850Unvested RSUs - 187Shares underlying convertible notes 20,157 23,557 53,718 48,834 These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Significant Accounting Policies [Abstract]
Schedule Of Property And Equipment Useful Lives	Manufacturing and office equipment5-7 yearsLeasehold improvementsShorter of useful life or remaining life of leaseFurniture and fixtures7 yearsComputer equipment and software3-5 years
Summary Of Anti-Dilutive Shares	2021 2020Options outstanding 23,215 12,240Warrants outstanding 10,346 12,850Unvested RSUs - 187Shares underlying convertible notes 20,157 23,557 53,718 48,834

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses [Abstract]
Schedule Of Prepaid Expenses	2021 2020Prepaid services$ 523 $ 408Prepaid bonds for German statutory costs - 142Prepaid insurance 23 21Prepaid licenses, software tools and support 16 11Other prepaid expenses 12 17  $ 574 $ 599

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	2021 2020Equipment and software$ 221 $ 218Leasehold improvements 19 19Furniture and fixtures - 30 240 267Less accumulated depreciation (233) (237) $ 7 $ 30

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Intangible Assets [Abstract]
Schedule Of Intangible Assets	2021 2020 Patents and copyrights$ 14,755 $ 14,948Less accumulated amortization (12,970) (12,778) $ 1,785 $ 2,170
Schedule Of Future Amortization Expense	2022$ 3092023 2782024 2652025 2262026 1552027 and thereafter 552Total$ 1,785

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities [Abstract]
Other Accrued Expenses	2021 2020Advances$ 500 $ 882Other accrued expenses 55 54 $ 555 $ 936

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Supplemental Cash Flow Information	Year Ended Year Ended December 31, December 31, 2021 2020Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 181 $ 315 Cash received for amounts included in the measurement of sublease assets: Operating cash flows from operating subleases 44 -
Supplemental Information	December 31, December 31, 2021 2020Weighted-average remaining lease term (in years): Operating leases 0.9 1.7 Operating subleases 0.9 -Weighted average discount rate Operating leases (1) 12.2% 12.1% (1)Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.
Future Maturities of Lease Liabilities	Operating Leases Operating Subleases2022 $ 166 $ (120)2023 4 -Thereafter - -Total undiscounted lease payments (receipts) 170 (120)Less: imputed interest (11) -Present value of lease liabilities (receivables) 159 (120)Less: current portion (155) 120Long-term lease obligations $ 4 $ -

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Instrument [Line Items]
Summary Of Aggregate Maturities	2022$ 942023 609Total$ 703
Schedule Of Convertible Notes Payable	Fixed Conversion Interest December 31,Description Rate Rate Maturity Date 2021 2020Convertible notes dated September 10, 2018 $0.40 8.0% September 10, 2023 $ 200 $ 600Convertible notes dated September 19, 2018 $0.57 8.0% September 19, 2023 425  425 Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 750 1,300 Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 320 340Convertible notes dated July 18, 2019 $0.08 7.5% July 18, 2024 700  700 Convertible notes dated September 13, 2019 $0.10 8.0% September 13, 2024 50  50 Convertible notes dated January 8, 2020 $0.13 8.0% January 8, 2025 1 450  450Total principal balance 2,895 3,865Less unamortized discount - 847 $ 2,895 $ 3,018
Secured Debt [Member]
Debt Instrument [Line Items]
Reconciliation Of Secured And Unsecured Contingent Obligation At Fair Value	2021 2020Secured contingent payment obligation, beginning of year $ 33,057 $ 26,651Change in fair value 4,315 6,406Secured contingent payment obligation, end of year $ 37,372 $ 33,057
Unsecured Debt [Member]
Debt Instrument [Line Items]
Reconciliation Of Secured And Unsecured Contingent Obligation At Fair Value	2021 2020Unsecured contingent payment obligations, beginning of period $ 5,222 $ -Reclassification of other liabilities - 1,003Issuance of contingent payment rights 412 2,258Change in fair value 57 1,961Unsecured contingent payment obligations, end of period $ 5,691 $ 5,222

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements [Abstract]
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis	Fair Value Measurements Total Quoted Prices in‎Active Markets‎(Level 1) Significant Other‎Observable‎Inputs (Level 2) Significant‎Unobservable‎Inputs (Level 3)December 31, 2021: Liabilities: Secured contingent payment obligation$ 37,372 $ - $ - $ 37,372Unsecured contingent payment obligations 5,691 - - 5,691 December 31, 2020: Liabilities: Secured contingent payment obligation 33,057 - - 33,057Unsecured contingent payment obligations 5,222 - - 5,222
Quantitative Information	Secured Contingent Payment Obligation Unsecured Contingent Payment ObligationsUnobservable Inputs Low Weighted Average High Low Weighted Average High Estimated undiscounted cash outflows (in millions) $0.0 $51.8 $79.6 $0.0 $8.1 $10.8Duration (in years) 0.5 2.3 3.5 1.5 2.5 3.5Estimated probabilities 7% 23% 25% 25% 25% 25%

Income Taxes And Tax Status (Ta

Income Taxes And Tax Status (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes And Tax Status [Abstract]
Schedule Of Effective Income Tax Rate Reconciliation	2021 2020Tax benefit at statutory rate$ (2,589) $ (4,111)State tax benefit (530) (842)Increase in valuation allowance 3,368 4,307Other (249) 646 $ - $ -
Schedule Of Deferred Tax Assets And Liabilities	2021 2020Gross deferred tax assets: Net operating loss carry-forward$ 78,600 $ 80,848Research and development credit carry-forward 6,028 6,603Stock compensation 356 122Patents and other 1,470 1,466Contingent payment obligations 6,341 5,235Fixed assets 53 54Accrued liabilities - 64Lease liabilities 38 77 92,886 94,469Less valuation allowance (92,886) (94,245) - 224Gross deferred tax liabilities: Convertible debt - (224) - (224)Net deferred tax asset$ - $ -
Schedule Of Unrecognized Tax Benefits Roll Forward	2021 2020Unrecognized tax benefits – beginning of year$ 927 $ 927Reduction as a result of lapse of statute of limitations (274) -Unrecognized tax benefits – end of year$ 653 $ 927

Stock Authorization And Issua_2

Stock Authorization And Issuance (Tables)	12 Months Ended
	Dec. 31, 2021
Stock Authorization and Issuance [Abstract]
Summary Of Equity Offerings	The following table presents a summary of completed equity-based financing transactions for the years ended December 31, 2020 and 2021 (in thousands, except for per share amounts): DateTransaction # of Common Shares/ Units Sold Average Price per Share/ Unit # of Warrants Issued‎(in 000’s) Average Exercise Price per Warrant Net Proceeds (1)January 2020Private placement of common stock 1,335 $0.13 - - $ 177February 2020Warrant amendment - - 5,000 $0.74 $ -March 2020Private placement of common stock, amended to add CPR 2,571 $0.35 - - $ 900April 2020 to December 2020Private placement of common stock with CPRs 10,858 $0.35 - - $ 3,724January 2021Private placement of common stock with CPRs 2,976 $0.35 - - $ 1,040March 2021Private placement of common stock with warrants 3,231 $1.29 1,619 $1.75 $ 4,156December 2021Private placement of common stock with warrants 1,053 $0.95 526 $1.00 $ 1,000 (1)After deduction of applicable offering costs. Net proceeds are inclusive of the value of the CPRs that are classified as long-term debt (see Note 9).

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Options Activity	Shares Weighted-‎Average‎Exercise Price Weighted-Average‎Remaining‎Contractual Term Aggregate‎Intrinsic‎Value ($)Outstanding at beginning of year 12,240 $ 0.28 Granted 13,040 0.54 Exercised (2,029) 0.17 Forfeited/Expired (36) 11.18 Outstanding at end of year 23,215 0.42 4.2 years $ 11,988Vested at end of year 16,676 $ 0.37 4.3 years $ 9,503
Summary Of Valuation Assumptions	Year ended December 31, 2021 2020Expected option term 14 years 5 yearsExpected volatility factor 2141.1% 127.4% to 135.3%Risk-free interest rate 30.36% 0.33% to 1.63%Expected annual dividend yield0% 0% 1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant.3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.
Summary Of Options And Warrants By Exercise Price Range	Options Outstanding Options VestedRange of Exercise Prices Number Outstanding at December 31, 2021 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2021 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life$0.171 - $0.33 9,289 $ 0.18 4.6 9,289 $ 0.18 4.6$0.50 - $0.75 13,553 0.54 4.0 7,014 0.54 4.0$1.98 - $2.97 373 2.02 2.5 373 2.02 2.5 23,215 $ 0.42 4.2 16,676 $ 0.37 4.3
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Restricted Stock Activity	Non-vested Shares Shares Weighted-Average‎Grant Date Fair ValueNon-vested at beginning of year 187 $ 0.33Granted 217 1.34Vested (404) 0.87Forfeited - -Non-vested at end of year - $ -

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)
Significant Accounting Policies [Line Items]
Operating segments | segment	1
Reportable segments | segment	1
Operating Lease, Liability	$ 11
Long-term Debt	703
Accumulated deficit	(433,412)	$ (421,361)
Operating Lease, Right-of-Use Asset	7	$ 10
Accounting Standards Update 2020-06 [Member]
Significant Accounting Policies [Line Items]
Long-term Debt	800
Accumulated deficit	300
Additional Paid in Capital	$ (1,100)
Patents And Copyrights [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	20 years
Patents And Copyrights [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life	15 years

Significant Accounting Polici_5

Significant Accounting Policies (Schedule Of Property And Equipment Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2021
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Minimum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Minimum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Maximum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Maximum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years

Significant Accounting Polici_6

Significant Accounting Policies (Summary Of Anti-Dilutive Shares) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	53,718	48,834
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	23,215	12,240
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	10,346	12,850
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares		187
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	20,157	23,557

Liquidity And Going Concern (De

Liquidity And Going Concern (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Liquidity And Going Concern [Abstract]
Net loss		$ (12,330)	$ (19,578)
Net cash used in operating activities		(7,702)	(4,777)
Accumulated deficit		(433,412)	(421,361)
Cash and cash equivalents		$ 1,030	$ 1,627
Net Proceeds	$ 3,000

Revenue (Details)

Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue [Abstract]
Contract with Customer, Liability, Revenue Recognized	$ 140,000	$ 0
Contract with Customer, Liability	0
Contract with Customer, Asset, before Allowance for Credit Loss	$ 0

Prepaid Expenses (Schedule Of P

Prepaid Expenses (Schedule Of Prepaid Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses [Abstract]
Prepaid services	$ 523	$ 408
Prepaid bonds for German statutory costs		142
Prepaid insurance	23	21
Prepaid licenses, software tools and support	16	11
Other prepaid expenses	12	17
Prepaid expenses	574	599
Other prepaid expenses and current assets	$ 500	$ 100

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Corporate Headquarters [Member]
Property, Plant and Equipment [Line Items]
Gain (loss) on sale of assets held for sale	$ (10)	$ 20
Property And Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 10	$ 30

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 240	$ 267
Less accumulated depreciation	(233)	(237)
Property, Plant and Equipment, Net, Total	7	30
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	221	218
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 19	19
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		$ 30

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Abstract]
Amortization expense	$ 350	$ 450
Loss on disposal	$ (30)	$ (300)

Intangible Assets (Schedule Of

Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Abstract]
Patents and copyrights	$ 14,755	$ 14,948
Accumulated amortization	(12,970)	(12,778)
Total	$ 1,785	$ 2,170

Intangible Assets (Schedule O_2

Intangible Assets (Schedule Of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets [Abstract]
2022	$ 309
2023	278
2024	265
2025	226
2026	155
2027 and thereafter	552
Total	$ 1,785	$ 2,170

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Details) $ in Millions	Dec. 31, 2020USD ($)
Accrued Liabilities [Abstract]
Amount Received From Investors	$ 0.4

Accrued Liabilities (Other Accr

Accrued Liabilities (Other Accrued Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities [Abstract]
Advances	$ 500	$ 882
Other accrued expenses	55	54
Accrued Liabilities	$ 555	$ 936

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property Subject to or Available for Operating Lease [Line Items]
Operating lease cost	$ 40	$ 100
Lease liability	11
Operating Lease, Lease Income, Lease Payments	$ 50
Corporate Office [Member] | Lake Mary Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Impairment loss		$ 200

Leases (Supplemental Cash Flow

Leases (Supplemental Cash Flow Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 181	$ 315
Operating cash flows from operating subleases	$ 44

Leases (Supplemental Informatio

Leases (Supplemental Information) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating leases	10 months 24 days	1 year 8 months 12 days
Operating subleases	10 months 24 days
Operating Lease, Weighted Average Discount Rate, Percent	12.20%	12.10%

Leases (Future Maturities of Le

Leases (Future Maturities of Lease Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	$ 166
2022	4
Total undiscounted lease payments	170
Less: imputed interest	(11)
Present value of lease liabilities	159
Less: current obligations under leases	(155)	$ (146)
Long-term lease obligations	4	$ 159
Operating Subleases [Member]
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	120
Total undiscounted lease payments	120
Present value of lease liabilities	120
Less: current obligations under leases	$ (120)

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	Mar. 31, 2021USD ($)	May 31, 2020USD ($)	Dec. 31, 2021USD ($)item$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2021USD ($)item$ / shares	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Fair value of note payable			$ 630,000		$ 630,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)			(4,372,000)	$ (8,367,000)
Brickell [Member]
Debt Instrument [Line Items]
Debt Instrument, Estimated Minimum Return			48,800,000	42,000,000
Mintz [Member]
Debt Instrument [Line Items]
Fees and expenses				0
Secured Debt [Member] | Brickell [Member]
Debt Instrument [Line Items]
Repayments of Debt					3,300,000
Proceeds from debt			$ 0	0	18,000,000
Secured Debt [Member] | Mintz [Member]
Debt Instrument [Line Items]
Repayments of Debt	$ 3,000,000
Notes payable				3,100,000
Unpaid fees and expenses				$ 3,600,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Shares issued | shares			272,000	710,000
Convertible notes dated January 8, 2020 [Member]
Debt Instrument [Line Items]
Reduced interest rate			2.00%
Note Payable To A Related Party [Member] | Unsecured Debt [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Debt			$ 700,000		$ 700,000
Interest expense			$ 30,000
Promissory Notes [Member] | Unsecured Debt [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Interest rate			4.00%		4.00%
Debt payment per month			$ 10,000
Final balloon payment			590,000		$ 590,000
Promissory Notes [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest expense			260,000	$ 470,000
Amortization			170,000
Outstanding principal converted			$ 970,000	$ 150,000
Shares issued | shares			3,400,000	750,000
Conversion price | $ / shares			$ 0.29	$ 0.20	$ 0.29
Aggregate common stock | item			20,200,000
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Measurement input | item			0.25		0.25
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Measurement input | item			0.20		0.20
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Measurement input | item			0.15		0.15
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Four [Member]
Debt Instrument [Line Items]
Measurement input | item			0.10		0.10
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Default Rate [Member]
Debt Instrument [Line Items]
Measurement input | item			0.12		0.12
Contingent Payment Obligation [Member] | Unsecured Debt [Member]
Debt Instrument [Line Items]
Common stock issued			$ 1,100,000	$ 3,800,000
Termination payment			2,600,000		$ 2,600,000	$ 5,000,000
Contingent Payment Obligation [Member] | Unsecured Debt [Member] | Termination Fee [Member]
Debt Instrument [Line Items]
Fair value of payment obligation				600,000			$ 400,000
Measurement input				600,000			$ 400,000
Paycheck Protection Program Loan [Member]
Debt Instrument [Line Items]
Proceeds from debt		$ 200,000
Contingent Payment Rights [Member] | Unsecured Debt [Member]
Debt Instrument [Line Items]
Common stock issued			400,000	1,800,000
Proceeds from debt			900,000
Fair value of payment obligation			3,100,000		3,100,000
Measurement input			3,100,000		3,100,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)			400,000
Contingent Payment Rights [Member] | Unsecured Debt [Member] | Measurement Input, Quotient [Member]
Debt Instrument [Line Items]
Fair value of payment obligation			10,000,000		10,000,000
Measurement input			10,000,000		10,000,000
Contingent Payment Rights [Member] | Unsecured Debt [Member] | Measurement Input, Investors Subscription [Member]
Debt Instrument [Line Items]
Fair value of payment obligation			10,000,000		10,000,000
Measurement input			10,000,000		10,000,000
Contingent Payment Rights [Member] | Unsecured Debt [Member] | Measurement Input, Investors Subscription, Aggregate [Member]
Debt Instrument [Line Items]
Fair value of payment obligation			5,800,000		5,800,000
Measurement input			$ 5,800,000		5,800,000
Maximum [Member] | Brickell [Member]
Debt Instrument [Line Items]
Percentage of proceeds payment			100.00%
Cumulative Effect, Period of Adoption, Adjustment [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Beneficial conversion feature				$ 800,000
Significant Other Observable Inputs (Level 2) [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Fair value of note payable			$ 2,300,000		$ 2,300,000

Long-Term Debt (Summary Of Aggr

Long-Term Debt (Summary Of Aggregate Maturities) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Debt [Abstract]
2022	$ 94
2023	609
Convertible notes, net	$ 703

Long-Term Debt (Schedule Of Con

Long-Term Debt (Schedule Of Convertible Notes Payable) (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Convertible notes, net	$ 2,895	$ 3,018
Convertible Debt [Member]
Debt Instrument [Line Items]
Total principal balance	2,895	3,865
Less Unamortized discount		847
Convertible notes, net	$ 2,895	3,018
Convertible Debt [Member] | Convertible Notes Dated September 10, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.40
Effective Interest Rate	8.00%
Total principal balance	$ 200	600
Convertible Debt [Member] | Convertible Note Dated September 19, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.57
Effective Interest Rate	8.00%
Total principal balance	$ 425	425
Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.25
Effective Interest Rate	8.00%
Total principal balance	$ 750	1,300
Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.10
Effective Interest Rate	8.00%
Total principal balance	$ 320	340
Convertible Debt [Member] | Convertible Note Dated July 18, 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.08
Effective Interest Rate	7.50%
Total principal balance	$ 700	700
Convertible Debt [Member] | Convertible Note Dated September 13, 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.10
Effective Interest Rate	8.00%
Total principal balance	$ 50	50
Convertible Debt [Member] | Convertible Notes Dated January 8, 2020 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.13
Effective Interest Rate	8.00%
Total principal balance	$ 450	$ 450

Long-Term Debt (Reconciliation

Long-Term Debt (Reconciliation Of Secured And Unsecured Contingent Obligation At Fair Value) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Secured Debt [Abstract]
Secured contingent payment obligation	$ 33,057
Secured contingent payment obligation	37,372	$ 33,057
Contingent Payment Obligation [Member] | Unsecured Debt [Member]
Secured Debt [Abstract]
Change in fair value	57	1,961
Unsecured Debt [Abstract]
Unsecured contingent payment obligation	5,222
Reclassification of other liabilities		1,003
Issuance of contingent payment rights	412	2,258
Change in fair value	57	1,961
Unsecured contingent payment obligation	5,691	5,222
Contingent Payment Obligation [Member] | Secured Debt [Member]
Secured Debt [Abstract]
Secured contingent payment obligation	33,057	26,651
Change in fair value	4,315	6,406
Secured contingent payment obligation	37,372	33,057
Unsecured Debt [Abstract]
Change in fair value	$ 4,315	$ 6,406

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details)	Dec. 31, 2021USD ($)item	Dec. 31, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets level 1 to Level 2 transfers	$ 0	$ 0
Assets level 2 to Level 1 transfers	0	0
Liabilities level 1 to Level 2 transfers	0	0
Liabilities level 2 to Level 1 transfers	0	$ 0
Fair value of note payable	$ 630,000
Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.1485
Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.0085
Measurement Input, Entity Credit Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.08
Measurement Input, Litigation Inherent Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.06

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 37,372	$ 33,057
Unsecured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	5,691	5,222
Quoted Prices In Active Markets (Level 1) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Quoted Prices In Active Markets (Level 1) [Member] | Unsecured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Other Observable Inputs (Level 2) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Other Observable Inputs (Level 2) [Member] | Unsecured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Unobservable Inputs (Level 3) [Member] | Secured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	37,372	33,057
Significant Unobservable Inputs (Level 3) [Member] | Unsecured Contingent Payment Obligation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 5,691	$ 5,222

Fair Value Measurements (Quanti

Fair Value Measurements (Quantitative Information) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)item
Unsecured Debt [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 0
Duration	1 year 6 months
Unsecured Debt [Member] | Minimum [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.25
Unsecured Debt [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 8.1
Duration	2 years 6 months
Unsecured Debt [Member] | Weighted Average [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.25
Unsecured Debt [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 10.8
Duration	3 years 6 months
Unsecured Debt [Member] | Maximum [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.25
Secured Debt [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 0
Duration	6 months
Secured Debt [Member] | Minimum [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.07
Secured Debt [Member] | Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 51.8
Duration	2 years 3 months 18 days
Secured Debt [Member] | Weighted Average [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.23
Secured Debt [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated cash outflows | $	$ 79.6
Duration	3 years 6 months
Secured Debt [Member] | Maximum [Member] | Estimated Probabilities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated probabilities | item	0.25

Income Taxes And Tax Status (Na

Income Taxes And Tax Status (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax Credit Carryforward [Line Items]
Foreign income tax expense
Current tax provision or benefit	$ 0	$ 0
Corporate tax rate	21.00%	21.00%
Operating loss carryforwards	$ 313,200,000
Operating loss carryforwards subject to expiration	276,600,000
Unrecognized tax benefits	653,000	$ 927,000	$ 927,000
Accrued interest or penalties	0	0
Income tax-related interest income, expense or penalties	0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, Amount	$ 6,000,000
Minimum [Member]
Tax Credit Carryforward [Line Items]
Period subject to IRS examination	2002
Maximum [Member]
Tax Credit Carryforward [Line Items]
Period subject to IRS examination	2021

Income Taxes And Tax Status (Sc

Income Taxes And Tax Status (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes And Tax Status [Abstract]
Tax benefit at statutory rate	$ (2,589)	$ (4,111)
State tax benefit	(530)	(842)
Increase in valuation allowance	3,368	4,307
Other	(249)	646
Income Tax Expense (Benefit), Total

Income Taxes And Tax Status (_2

Income Taxes And Tax Status (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Taxes And Tax Status [Abstract]
Net operating loss carry-forward	$ 78,600	$ 80,848
Research and development credit carry-forward	6,028	6,603
Stock compensation	356	122
Patents and other	1,470	1,466
Contingent payment obligations	6,341	5,235
Fixed assets	53	54
Accrued liabilities		64
Lease liabilities	38	77
Deferred tax assets, gross	92,886	94,469
Less valuation allowance	(92,886)	(94,245)
Net deferred tax asset		224
Convertible debt		(224)
Deferred tax liabilities, gross		(224)
Net deferred tax asset

Income Taxes And Tax Status (_3

Income Taxes And Tax Status (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes And Tax Status [Abstract]
Unrecognized tax benefits, beginning of year	$ 927	$ 927
Reduction as a result of lapse of statute of limitations	(274)
Unrecognized tax benefits, end of year	$ 653	$ 927

Commitments And Contingencies (

Commitments And Contingencies (Details) $ in Thousands

Mar. 22, 2022item

Feb. 28, 2022item

Jan. 31, 2022item

Dec. 31, 2021USD ($)item

Nov. 30, 2021item

Jun. 30, 2021item

May 31, 2021item

Jul. 31, 2020item

Jun. 30, 2020item

May 31, 2020item

Apr. 30, 2020item

Feb. 29, 2020item

Jul. 31, 2019item

Mar. 31, 2018item

Mar. 31, 2017item

Dec. 31, 2015item

Dec. 31, 2021USD ($)item

Dec. 31, 2020USD ($)

Commitments and Contingencies [Line Items]

Accrued costs | $

$ 555

$ 555

$ 936

ParkerVision v. LG Electronics [Member]

Commitments and Contingencies [Line Items]

Number of additional patents allegedly infringed upon

2

Additional number of patents subject to Inter Parter review

2

ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of petitions

6

Number of patents allegedly infringed upon

4

Number of patents dismissed

3

Claim construction

7

2

ParkerVision v. Intel II (Western District of Texas) [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon

2

1

Number of patents found not infringed upon

2

ParkerVision v. Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of petitions

6

Number of asserted patents

4

Number of patents allegedly infringed upon

4

Number of patents found infringed upon

2

Number of patents found not infringed upon

3

Estimated loss | $

$ 1,300,000

$ 1,300,000

ParkerVision v. TCL (Western District of Texas) [Member]

Commitments and Contingencies [Line Items]

Number of additional patents allegedly infringed upon

2

Number of patents subject to Inter Partes review

2

Number of asserted patents

10

Number of patents allegedly infringed upon

8

TCL, et. al. v. ParkerVision (PTAB) [Member]

Commitments and Contingencies [Line Items]

Number of patents subject to Inter Partes review

2

Subsequent Event [Member] | ParkerVision V. Intel (Western District of Texas) [Member]

Commitments and Contingencies [Line Items]

Number of additional patents allegedly infringed upon

6

Number of patents allegedly infringed upon

2

Number of asserted patents

6

Subsequent Event [Member] | Intel v. ParkerVision (PTAB) [Member]

Commitments and Contingencies [Line Items]

Number of additional patents allegedly infringed upon

1

Number of patents subject to Inter Partes review

2

Number of claims to institute trial

7

Number of patents allegedly infringed upon

2

Number of patents found infringed upon

1

Subsequent Event [Member] | ParkerVision v. Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Maximum [Member] | ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]

Commitments and Contingencies [Line Items]

Claim construction

10

Stock Authorization and Issua_3

Stock Authorization and Issuance (Narrative) (Details) - USD ($)	Apr. 06, 2021	Jan. 12, 2021	Oct. 30, 2020	Jul. 14, 2020	Jun. 08, 2020	Mar. 16, 2020	Feb. 10, 2020	Nov. 29, 2005	Dec. 31, 2021	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Jan. 31, 2021	Mar. 31, 2020	Jan. 31, 2020	Dec. 31, 2021	Aug. 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Nov. 20, 2020	Jul. 31, 2020	Jun. 30, 2020	Feb. 28, 2020	Dec. 31, 2019	Nov. 17, 2005
Stock Authorization And Issuance [Line Items]
Common stock, shares authorized									150,000,000							150,000,000		140,000,000	150,000,000	140,000,000	150,000,000		140,000,000	110,000,000
Preferred Stock, Shares authorized									15,000,000							15,000,000			15,000,000								100,000
Preferred Stock, Shares outstanding									0							0			0
Exercise price per warrant									$ 1			$ 1.75				$ 1			$ 1
Class of Warrant or Right, Weighted Average Remaining Life																			3 years
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants									$ 526,315			$ 1,619,289
Sale of common stock, number of shares									1,052,631			3,230,942	2,976,430			4,986,292,000,000	5,871,584
Sale of common stock													$ 1,000,000
Sale of stock price per share									$ 0.95			$ 1.29	$ 0.35			$ 0.95			$ 0.95
Proceeds from sale of common stock									$ 1,000,000			$ 4,200,000
Shares of common stock issued upon exercise of warrants																			10,300,000	12,900,000
Estimated fair market value									$ 3,200,000							$ 3,200,000		$ 1,700,000	$ 3,200,000	$ 1,700,000
Issuance of common stock for services, shares											35,000		500,000
Issuance of stocks to consultants, value											$ 40,000		$ 330,000
Proceeds from Warrant Exercises												$ 3,000,000
Warrants, Options And Unvested RSUs [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance									33,600,000							33,600,000			33,600,000
Aspire Capital [Member]
Stock Authorization And Issuance [Line Items]
Warrants Beneficially Own																			9.99%
Warrants Beneficially Own, Prior Notice																			61 days
Aspire Capital, Amendment [Member]
Stock Authorization And Issuance [Line Items]
Warrants to purchase common stock																									5,000,000
Exercise price per warrant									$ 0.001							$ 0.001			$ 0.001
Non-cash warrant expense																			$ 1,780,000
warrants exercised																			1,430,000
Proceeds from Warrant Exercises																			$ 500,000
New Aspire Warrant [Member]
Stock Authorization And Issuance [Line Items]
Warrants to purchase common stock																									5,000,000
Exercise price per warrant																									$ 0.74
warrants exercised																			500,000	3,070,000
Proceeds from Warrant Exercises																			$ 200,000	$ 1,100,000
Series E Preferred Stock [Member]
Stock Authorization And Issuance [Line Items]
Preferred Stock, Shares outstanding									0							0			0
Consultants [Member] | Chelsea Investor Relations [Member]
Stock Authorization And Issuance [Line Items]
Issuance of common stock for services, shares							500,000
Issuance of stocks to consultants, value							$ 150,000
Agreement term																			24 months
Consultants [Member] | Tailwinds Research Group LLC [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant						$ 1
Issuance of common stock for services, shares						200,000
Proceeds from Warrant Exercises						$ 60,000
Shareholder Approved Equity Compensation Plans [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance									2,000,000							2,000,000			2,000,000
Long Term Incentive Plan, 2019 [Member] | Restricted Stock Award [Member]
Stock Authorization And Issuance [Line Items]
Granted, Shares									217,143
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested																			$ 300,000
Minimum [Member] | Aspire Capital, Amendment [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant																									0.35
Maximum [Member] | Aspire Capital [Member]
Stock Authorization And Issuance [Line Items]
Warrants Beneficially Own																			19.99%
Maximum [Member] | Aspire Capital, Amendment [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant																									$ 0.74
Weighted Average [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant									$ 0.75							$ 0.75			$ 0.75
Third Party [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock, number of shares			70,000
Sale of common stock			$ 20,000
Principal [Member] | Convertible Debt [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance									20,200,000							20,200,000			20,200,000
Interest In-Kind [Member] | Convertible Debt [Member]
Stock Authorization And Issuance [Line Items]
Shares reserved for issuance									3,200,000							3,200,000			3,200,000
Rights Agreement [Member]
Stock Authorization And Issuance [Line Items]
Redemption price									$ 0.01							$ 0.01			$ 0.01
Exercise price per warrant								$ 8.54
Threshold percentage at which rights separate from common stock								15.00%
Rights Agreement [Member] | Minimum [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant																						$ 14.50
Rights Agreement [Member] | Maximum [Member]
Stock Authorization And Issuance [Line Items]
Exercise price per warrant																						$ 8.54
Private Placements With Accredited Investors [Member]
Stock Authorization And Issuance [Line Items]
Proceeds from issuance of common stock														$ 900,000	$ 200,000			3,800,000
Aggregate offering price														$ 0.35				$ 0.35		$ 0.35
Aggregate offering shares														2,571,432				10,857,876		10,857,876
Unsecured Debt														$ 900,000				$ 1,800,000		$ 1,800,000
Private Placements With Accredited Investors B [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price															$ 0.13
Aggregate offering shares															1,169,232
Private Placements With Accredited Investors C [Member]
Stock Authorization And Issuance [Line Items]
Aggregate offering price															$ 0.15
Aggregate offering shares															166,667
Securities Purchase Agreements [Member] | Third Party [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock, number of shares					30,000
Sale of common stock					$ 10,000
Intro-Act [Member]
Stock Authorization And Issuance [Line Items]
Issuance of common stock for services, shares	50,000	50,000	50,000	50,000						100,000
Issuance of stocks to consultants, value										$ 120,000									$ 100,000	50,000
Contingent Payment Obligation [Member]
Stock Authorization And Issuance [Line Items]
Sale of common stock													$ 400,000
Contingent Payment Obligation [Member] | Unsecured Debt [Member]
Stock Authorization And Issuance [Line Items]
Unsecured Debt									$ 5,691,000							$ 5,691,000		$ 5,222,000	5,691,000	$ 5,222,000
Contingent Payment Rights [Member] | Unsecured Debt [Member]
Stock Authorization And Issuance [Line Items]
Fair value of payment obligation									$ 3,100,000							$ 3,100,000			$ 3,100,000
Contingent Payment Rights [Member] | Third Party [Member] | Unsecured Debt [Member]
Stock Authorization And Issuance [Line Items]
Fair value of payment obligation			$ 100,000
Unsecured Debt			$ 20,000

Stock Authorization And Issua_4

Stock Authorization And Issuance (Summary Of Equity Offerings) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 31, 2021	Jan. 31, 2021	Dec. 31, 2021
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 1,000,000
Average Exercise Price Per Warrant	$ 1.75		$ 1
Net Proceeds	$ 3,000,000
Aspire Capital, Amendment [Member]
Equity Offerings [Line Items]
Average Exercise Price Per Warrant			$ 0.001
Net Proceeds			$ 500,000
Common Stock [Member] | Private Placement Of Common Stock [Member] | January 2020 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 1,335
Average Price per Share/Unit			$ 0.13
Net Proceeds			$ 177,000
Common Stock [Member] | Private Placement Of Common Stock, Amended To Add CPR [Member] | March 2020 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 2,571
Average Price per Share/Unit			$ 0.35
Net Proceeds			$ 900,000
Common Stock [Member] | Private Placement Of Common Stock With CPRs [Member] | April 2020 to December 2020 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 10,858
Average Price per Share/Unit			$ 0.35
Net Proceeds			$ 3,724,000
Common Stock [Member] | Private Placement Of Common Stock With CPRs [Member] | January 2021 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 2,976
Average Price per Share/Unit			$ 0.35
Net Proceeds			$ 1,040,000
Common Stock [Member] | Private Placement Of Common Stock With Warrants [Member] | March 2021 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 3,231
Average Price per Share/Unit			$ 1.29
Number of warrants issued			1,619,000
Average Exercise Price Per Warrant			$ 1.75
Net Proceeds			$ 4,156,000
Common Stock [Member] | Private Placement Of Common Stock With Warrants [Member] | December 2021 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold			$ 1,053
Average Price per Share/Unit			$ 0.95
Number of warrants issued			526,000
Average Exercise Price Per Warrant			$ 1
Net Proceeds			$ 1,000,000
Warrants Outstanding [Member] | Warrant Amendment [Member] | February 2020 [Member]
Equity Offerings [Line Items]
Number of warrants issued			5,000,000
Average Exercise Price Per Warrant			$ 0.74

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, net of estimated forfeitures			$ 3,000,000
Expected weighted average period to recognize the compensation cost, in years			1 year
Total share-based expense			$ 3,300,000	$ 1,200,000
Number of shares authorized		27,000,000			12,000,000
Issuance of common stock for services, shares	35,000	500,000
Issuance of stocks to consultants, value	$ 40,000	$ 330,000
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant			20,473
Maximum number of shares per employee			5,000
Number of shares authorized			50,000
2011 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant			61,302
Maximum number of shares per employee			150,000
Number of shares authorized			3,000,000
2019 Long-Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant			1,897,857
Number of shares authorized					12,000,000
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested fair value			$ 600,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of option shares granted			$ 0.46	$ 0.27
Fair market value of vested shares			$ 3,400,000	$ 900,000
Intrinsic value of options exercised			$ 300,000	$ 0
Granted, Shares			13,040,000
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Named Executive Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares		11,900,000
Non Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares		1,100,000
Non Employee Directors [Member] | Maximum [Member] | 2019 Long-Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares per employee			1,000,000
Weighted average fair value of option shares granted			$ 175,000
Non Employee [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Executive Officers, Key Employees And Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price		$ 0.54

Share-Based Compensation (Summa

Share-Based Compensation (Summary Of Restricted Stock Activity) (Details) - Restricted Stock Award And Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at beginning of year, Shares | shares	187
Granted, Shares | shares	217
Vested, Shares | shares	(404)
Non-vested at beginning of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 0.33
Granted, Weighted Average Grant Date Fair Value | $ / shares	1.34
Vested, Weighted Average Grant Date Fair Value | $ / shares	$ 0.87

Share-Based Compensation (Sum_2

Share-Based Compensation (Summary Of Option Activity) (Details) - Stock Options [Member] $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Shares, Beginning of year | shares	12,240
Granted, Shares | shares	13,040
Exercised, Shares | shares	(2,029)
Forfeited, Shares | shares	(36)
Outstanding, Shares, End of year | shares	23,215
Outstanding, Weighted Average Exercise Price, Beginning of year | $ / shares	$ 0.28
Granted, Weighted Average Exercise Price | $ / shares	0.54
Exercised, Weighted Average Exercise Price | $ / shares	0.17
Forfeited, Weighted Average Exercise Price | $ / shares	11.18
Outstanding, Weighted Average Exercise Price, End of year | $ / shares	$ 0.42
Outstanding, Weighted Average Remaining Contractual Term	4 years 2 months 12 days
Outstanding, Aggregate Intrinsic Value | $	$ 11,988
Vested and expected to vest at end of year, shares | shares	16,676
Vested and expected to vest at end of year, weighted average exercise price | $ / shares	$ 0.37
Vested and expected to vest at end of year, weighted average remaining contractual term	4 years 3 months 18 days
Vested and expected to vest at end of year, aggregate intrinsic value | $	$ 9,503

Share-Based Compensation (Sum_3

Share-Based Compensation (Summary Of Valuation Assumptions) (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term	4 years	5 years
Expected annual dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility factor	141.10%	127.40%
Risk-free interest rate	0.36%	0.33%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility factor		135.30%
Risk-free interest rate		1.63%

Share-Based Compensation (Sum_4

Share-Based Compensation (Summary Of Options And Warrants By Exercise Price Range) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Options Outstanding
Number Outstanding | shares	23,215
Wtd. Avg. Exercise Price	$ 0.42
Wtd. Avg. Remaining Contractual Life	4 years 2 months 12 days
Options Vested
Number Exercisable | shares	16,676
Wtd. Avg. Exercise Price	$ 0.37
Wtd. Avg. Remaining Contractual Life	4 years 3 months 18 days
$0.171 - $0.33 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price minimum	$ 0.171
Exercise price maximum	$ 0.33
Options Outstanding
Number Outstanding | shares	9,289
Wtd. Avg. Exercise Price	$ 0.18
Wtd. Avg. Remaining Contractual Life	4 years 7 months 6 days
Options Vested
Number Exercisable | shares	9,289
Wtd. Avg. Exercise Price	$ 0.18
Wtd. Avg. Remaining Contractual Life	4 years 7 months 6 days
$0.50 - $0.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price minimum	$ 0.50
Exercise price maximum	$ 0.75
Options Outstanding
Number Outstanding | shares	13,553
Wtd. Avg. Exercise Price	$ 0.54
Wtd. Avg. Remaining Contractual Life	4 years
Options Vested
Number Exercisable | shares	7,014
Wtd. Avg. Exercise Price	$ 0.54
Wtd. Avg. Remaining Contractual Life	4 years
$1.98 - $2.13 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price minimum	$ 1.98
Exercise price maximum	$ 2.97
Options Outstanding
Number Outstanding | shares	373
Wtd. Avg. Exercise Price	$ 2.02
Wtd. Avg. Remaining Contractual Life	2 years 6 months
Options Vested
Number Exercisable | shares	373
Wtd. Avg. Exercise Price	$ 2.02
Wtd. Avg. Remaining Contractual Life	2 years 6 months

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended		24 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Mar. 31, 2021	Jan. 31, 2021	Jan. 31, 2020
Related Party Transaction [Line Items]
Sale of stock price per share	$ 0.95		$ 0.95	$ 1.29	$ 0.35
Common stock, shares issued	76,992,000	58,591,000	76,992,000
Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party	$ 100	$ 10
Stacie Wilf [Member]
Related Party Transaction [Line Items]
Accounts payable						$ 80
Common stock, shares issued						500,000
Promissory Notes [Member] | Unsecured Debt [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party			$ 100
Secured notes payable	$ 700		$ 700

Subsequent Events (Details)

Subsequent Events (Details) - item	Mar. 22, 2022	Feb. 28, 2022	Jan. 31, 2022	Jun. 30, 2021	May 31, 2021	Jul. 31, 2020	Jun. 30, 2020	May 31, 2020	Mar. 31, 2017
ParkerVision v. LG Electronics [Member]
Subsequent Event [Line Items]
Number of additional patents allegedly infringed upon				2
ParkerVision V. Intel (Western District of Texas) [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of patents allegedly infringed upon		2
Number of additional patents allegedly infringed upon		6
Intel v. ParkerVision (PTAB) [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of patents allegedly infringed upon			2
Number of additional patents allegedly infringed upon			1
Number of patents subject to Inter Partes review			2
Number of claims to institute trial			7
Number of patents found infringed upon			1
ParkerVision v. Intel II (Western District of Texas) [Member]
Subsequent Event [Line Items]
Number of patents allegedly infringed upon						2	1
ParkerVision v. Qualcomm (Middle District of Florida) [Member]
Subsequent Event [Line Items]
Number of patents found infringed upon									2
ParkerVision v. Qualcomm (Middle District of Florida) [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of patents allegedly infringed upon	3
ParkerVision v. TCL (Western District of Texas) [Member]
Subsequent Event [Line Items]
Number of additional patents allegedly infringed upon								2
Number of patents subject to Inter Partes review					2